[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f7AKNZR92o7k4Xv2Ghqfy-41igzp-QRS1zZy_xGThkOc":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":85,"rows":92},"Queen Mary University of London",[4],246,false,75,17,552525,39,175,[14,17,19,21,24,27,29,32],{"name":15,"count":16},"Cardiovascular Diseases",8,{"name":18,"count":16},"Multiple Sclerosis",{"name":20,"count":16},"Breast Cancer",{"name":22,"count":23},"Hypertension",7,{"name":25,"count":26},"Smoking Cessation",6,{"name":28,"count":26},"Myocardial Infarction",{"name":30,"count":31},"Periodontitis",5,{"name":33,"count":34},"Wound Heal",4,[36,41,46,51,56,60,65,70,75,80],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT05600062","Influence of NEP Inhibition on Vascular Leak and Inflammation (NEPi-INFLAMMATION)","2026-02-01","Racecadotril 100 milligram (MG) Oral",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT04889274","Investigation of the Effects of Dietary Nitrate and Sex on COVID-19 Vaccine Induced Vascular Dysfunction in Healthy Men and Women (DiNOVasc-COVID-19)","2026-04-30","COVID-19 vaccine",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT04624399","Neoadjuvant Immune Checkpoint Inhibitor Treatment in Urothelial Cancer","2026-05-30","Atezolizumab",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT05994742","An Adaptive Multi-arm Trial to Improve Clinical Outcomes Among Children Recovering From Complicated SAM","2026-08-15","Rifampicin",{"nctId":57,"briefTitle":58,"date":59,"intervention":50},"NCT05498896","Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC","2026-08-31",{"nctId":61,"briefTitle":62,"date":63,"intervention":64},"NCT06309719","Hyaluronic Acid and Polynucleotides for Supra-bony Defects","2026-12","Periodontal Access Flap",{"nctId":66,"briefTitle":67,"date":68,"intervention":69},"NCT06892860","Comparing 3 vs 6 Cycles of Platinum-based Chemotherapy Prior to Maintenance Avelumab in Advanced Urothelial Cancer","2027-06-30","Avelumab",{"nctId":71,"briefTitle":72,"date":73,"intervention":74},"NCT05248919","Therapy for Hepatitis C Virus (HCV) in Primary Treatment Failure in Pakistan","2027-09-01","Epclusa (nucleotide HCV NS5B polymerase inhibitors).",{"nctId":76,"briefTitle":77,"date":78,"intervention":79},"NCT04995224","Mechanism of Chronic Pain in Patients With IBD","2027-09-30","Assessment of Biological factors",{"nctId":81,"briefTitle":82,"date":83,"intervention":84},"NCT05418010","Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)","2027-10-31","Tyruko Injectable Product",[86,87,88,89,90,91],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[93,127,145,163,181,199,217,245,263,281,299,325,385,425,466,488,510,531,549,567,594,612,630,648,673,691,714,732,750,787,813,834,857,879,906,924,946,964,992,1017,1051,1077,1100,1118,1143,1169,1187,1205,1251,1296,1318,1352,1370,1399,1417,1435,1453,1471,1489,1507,1531,1555,1573,1599,1617,1666,1697,1719,1744,1772,1795,1820,1838,1864,1882,1900,1918,1936,1964,1982,2000,2024,2048,2066,2093,2111,2129,2147,2175,2193,2211,2234,2252,2270,2288,2306,2332,2359,2377,2395,2422,2440,2458,2476,2509,2534,2559,2577,2595,2620,2644,2673,2691,2718,2736,2754,2781,2799,2826],{"intervention":94,"totalTrials":95,"cells":96},"Rivaroxaban",1,{"EARLY_PHASE1":97,"PHASE1":100,"PHASE2":102,"PHASE3":104,"PHASE4":123,"NA":125},{"trials":98,"activeCount":99},[],0,{"trials":101,"activeCount":99},[],{"trials":103,"activeCount":99},[],{"trials":105,"activeCount":95,"soonestReadout":111},[106],{"nctId":107,"briefTitle":108,"status":109,"phases":110,"primaryCompletion":111,"completion":111,"start":112,"enrollment":113,"conditions":114,"interventions":117},"NCT06370273","Thromboprophylaxis in Lower Limb Immobilisation","RECRUITING",[89],"2028-08-31","2024-11-12",10044,[115,116],"Thrombosis","Injury Leg",[94,118,119,120,121,122],"Apixaban","Enoxaparin Injectable Solution","Tinzaparin Injectable Solution","Dalteparin Injectable Solution","Fondaparinux Injectable Product",{"trials":124,"activeCount":99},[],{"trials":126,"activeCount":99},[],{"intervention":118,"totalTrials":95,"cells":128},{"EARLY_PHASE1":129,"PHASE1":131,"PHASE2":133,"PHASE3":135,"PHASE4":141,"NA":143},{"trials":130,"activeCount":99},[],{"trials":132,"activeCount":99},[],{"trials":134,"activeCount":99},[],{"trials":136,"activeCount":95,"soonestReadout":111},[137],{"nctId":107,"briefTitle":108,"status":109,"phases":138,"primaryCompletion":111,"completion":111,"start":112,"enrollment":113,"conditions":139,"interventions":140},[89],[115,116],[94,118,119,120,121,122],{"trials":142,"activeCount":99},[],{"trials":144,"activeCount":99},[],{"intervention":119,"totalTrials":95,"cells":146},{"EARLY_PHASE1":147,"PHASE1":149,"PHASE2":151,"PHASE3":153,"PHASE4":159,"NA":161},{"trials":148,"activeCount":99},[],{"trials":150,"activeCount":99},[],{"trials":152,"activeCount":99},[],{"trials":154,"activeCount":95,"soonestReadout":111},[155],{"nctId":107,"briefTitle":108,"status":109,"phases":156,"primaryCompletion":111,"completion":111,"start":112,"enrollment":113,"conditions":157,"interventions":158},[89],[115,116],[94,118,119,120,121,122],{"trials":160,"activeCount":99},[],{"trials":162,"activeCount":99},[],{"intervention":120,"totalTrials":95,"cells":164},{"EARLY_PHASE1":165,"PHASE1":167,"PHASE2":169,"PHASE3":171,"PHASE4":177,"NA":179},{"trials":166,"activeCount":99},[],{"trials":168,"activeCount":99},[],{"trials":170,"activeCount":99},[],{"trials":172,"activeCount":95,"soonestReadout":111},[173],{"nctId":107,"briefTitle":108,"status":109,"phases":174,"primaryCompletion":111,"completion":111,"start":112,"enrollment":113,"conditions":175,"interventions":176},[89],[115,116],[94,118,119,120,121,122],{"trials":178,"activeCount":99},[],{"trials":180,"activeCount":99},[],{"intervention":121,"totalTrials":95,"cells":182},{"EARLY_PHASE1":183,"PHASE1":185,"PHASE2":187,"PHASE3":189,"PHASE4":195,"NA":197},{"trials":184,"activeCount":99},[],{"trials":186,"activeCount":99},[],{"trials":188,"activeCount":99},[],{"trials":190,"activeCount":95,"soonestReadout":111},[191],{"nctId":107,"briefTitle":108,"status":109,"phases":192,"primaryCompletion":111,"completion":111,"start":112,"enrollment":113,"conditions":193,"interventions":194},[89],[115,116],[94,118,119,120,121,122],{"trials":196,"activeCount":99},[],{"trials":198,"activeCount":99},[],{"intervention":122,"totalTrials":95,"cells":200},{"EARLY_PHASE1":201,"PHASE1":203,"PHASE2":205,"PHASE3":207,"PHASE4":213,"NA":215},{"trials":202,"activeCount":99},[],{"trials":204,"activeCount":99},[],{"trials":206,"activeCount":99},[],{"trials":208,"activeCount":95,"soonestReadout":111},[209],{"nctId":107,"briefTitle":108,"status":109,"phases":210,"primaryCompletion":111,"completion":111,"start":112,"enrollment":113,"conditions":211,"interventions":212},[89],[115,116],[94,118,119,120,121,122],{"trials":214,"activeCount":99},[],{"trials":216,"activeCount":99},[],{"intervention":55,"totalTrials":95,"cells":218},{"EARLY_PHASE1":219,"PHASE1":221,"PHASE2":223,"PHASE3":225,"PHASE4":241,"NA":243},{"trials":220,"activeCount":99},[],{"trials":222,"activeCount":99},[],{"trials":224,"activeCount":99},[],{"trials":226,"activeCount":95,"soonestReadout":54},[227],{"nctId":52,"briefTitle":53,"status":228,"phases":229,"primaryCompletion":54,"completion":54,"start":230,"enrollment":231,"conditions":232,"interventions":237},"ACTIVE_NOT_RECRUITING",[89],"2024-07-15",674,[233,234,235,236],"Severe Acute Malnutrition","HIV","Comorbidities and Coexisting Conditions","Child Malnutrition",[55,238,239,240],"Azithromycin","Isoniazid","Pyridoxine Hydrochloride",{"trials":242,"activeCount":99},[],{"trials":244,"activeCount":99},[],{"intervention":238,"totalTrials":95,"cells":246},{"EARLY_PHASE1":247,"PHASE1":249,"PHASE2":251,"PHASE3":253,"PHASE4":259,"NA":261},{"trials":248,"activeCount":99},[],{"trials":250,"activeCount":99},[],{"trials":252,"activeCount":99},[],{"trials":254,"activeCount":95,"soonestReadout":54},[255],{"nctId":52,"briefTitle":53,"status":228,"phases":256,"primaryCompletion":54,"completion":54,"start":230,"enrollment":231,"conditions":257,"interventions":258},[89],[233,234,235,236],[55,238,239,240],{"trials":260,"activeCount":99},[],{"trials":262,"activeCount":99},[],{"intervention":239,"totalTrials":95,"cells":264},{"EARLY_PHASE1":265,"PHASE1":267,"PHASE2":269,"PHASE3":271,"PHASE4":277,"NA":279},{"trials":266,"activeCount":99},[],{"trials":268,"activeCount":99},[],{"trials":270,"activeCount":99},[],{"trials":272,"activeCount":95,"soonestReadout":54},[273],{"nctId":52,"briefTitle":53,"status":228,"phases":274,"primaryCompletion":54,"completion":54,"start":230,"enrollment":231,"conditions":275,"interventions":276},[89],[233,234,235,236],[55,238,239,240],{"trials":278,"activeCount":99},[],{"trials":280,"activeCount":99},[],{"intervention":240,"totalTrials":95,"cells":282},{"EARLY_PHASE1":283,"PHASE1":285,"PHASE2":287,"PHASE3":289,"PHASE4":295,"NA":297},{"trials":284,"activeCount":99},[],{"trials":286,"activeCount":99},[],{"trials":288,"activeCount":99},[],{"trials":290,"activeCount":95,"soonestReadout":54},[291],{"nctId":52,"briefTitle":53,"status":228,"phases":292,"primaryCompletion":54,"completion":54,"start":230,"enrollment":231,"conditions":293,"interventions":294},[89],[233,234,235,236],[55,238,239,240],{"trials":296,"activeCount":99},[],{"trials":298,"activeCount":99},[],{"intervention":300,"totalTrials":95,"cells":301},"Cladribine",{"EARLY_PHASE1":302,"PHASE1":304,"PHASE2":306,"PHASE3":308,"PHASE4":321,"NA":323},{"trials":303,"activeCount":99},[],{"trials":305,"activeCount":99},[],{"trials":307,"activeCount":99},[],{"trials":309,"activeCount":95,"soonestReadout":314},[310],{"nctId":311,"briefTitle":312,"status":228,"phases":313,"primaryCompletion":314,"completion":314,"start":315,"enrollment":316,"conditions":317,"interventions":320},"NCT04695080","ChariotMS - Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis",[88,89],"2027-12-31","2021-06-25",204,[318,319],"Advanced Multiple Sclerosis","Progressive Multiple Sclerosis",[300],{"trials":322,"activeCount":99},[],{"trials":324,"activeCount":99},[],{"intervention":50,"totalTrials":34,"cells":326},{"EARLY_PHASE1":327,"PHASE1":329,"PHASE2":345,"PHASE3":379,"PHASE4":381,"NA":383},{"trials":328,"activeCount":99},[],{"trials":330,"activeCount":99},[331],{"nctId":332,"briefTitle":333,"status":334,"phases":335,"primaryCompletion":336,"completion":337,"start":338,"enrollment":99,"conditions":339,"interventions":341},"NCT03498222","Study in Patients With Tumours Requiring Arginine to Assess ADI-PEG 20 With Atezolizumab, Pemetrexed and Carboplatin","WITHDRAWN",[87],"2020-01-31","2021-12-31","2018-06-01",[340],"Carcinoma, Non-Small-Cell Lung",[50,342,343,344],"Pemetrexed","Carboplatin","ADI PEG20",{"trials":346,"activeCount":378,"soonestReadout":49},[347,358,371],{"nctId":57,"briefTitle":58,"status":228,"phases":348,"primaryCompletion":59,"completion":59,"start":349,"enrollment":350,"conditions":351,"interventions":353},[88],"2018-12-19",146,[352],"Triple Negative Breast Cancer",[50,354,355,356,357],"Ipatasertib","Paclitaxel","Doxorubicin","Cyclophosphamide",{"nctId":359,"briefTitle":360,"status":361,"phases":362,"primaryCompletion":363,"completion":363,"start":364,"enrollment":365,"conditions":366,"interventions":368},"NCT03395899","Pre-operative Immunotherapy Combination Strategies in Breast Cancer","COMPLETED",[88],"2023-08-18","2017-12-21",71,[20,367],"Estrogen Receptor-positive Breast Cancer",[50,369,354,370],"Cobimetinib","Bevacizumab",{"nctId":47,"briefTitle":48,"status":109,"phases":372,"primaryCompletion":49,"completion":49,"start":373,"enrollment":374,"conditions":375,"interventions":377},[88],"2021-06-17",58,[376],"Urogenital Cancer",[50],2,{"trials":380,"activeCount":99},[],{"trials":382,"activeCount":99},[],{"trials":384,"activeCount":99},[],{"intervention":355,"totalTrials":386,"cells":387},3,{"EARLY_PHASE1":388,"PHASE1":390,"PHASE2":392,"PHASE3":419,"PHASE4":421,"NA":423},{"trials":389,"activeCount":99},[],{"trials":391,"activeCount":99},[],{"trials":393,"activeCount":95,"soonestReadout":59},[394,405,409],{"nctId":395,"briefTitle":396,"status":361,"phases":397,"primaryCompletion":398,"completion":399,"start":400,"enrollment":365,"conditions":401,"interventions":403},"NCT02423603","PAKT: AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer",[88],"2017-06-30","2024-06-30","2014-05-14",[402],"Metastatic Breast Cancer",[355,404],"AZD5363",{"nctId":57,"briefTitle":58,"status":228,"phases":406,"primaryCompletion":59,"completion":59,"start":349,"enrollment":350,"conditions":407,"interventions":408},[88],[352],[50,354,355,356,357],{"nctId":410,"briefTitle":411,"status":334,"phases":412,"primaryCompletion":413,"completion":414,"start":415,"enrollment":99,"conditions":416,"interventions":417},"NCT03841747","Paclitaxel Plus Pembrolizumab vs. Paclitaxel Weekly in ER+ Luminal B Metastatic Breast Cancer",[88],"2023-06","2025-06","2020-12",[20],[418,355],"Pembrolizumab",{"trials":420,"activeCount":99},[],{"trials":422,"activeCount":99},[],{"trials":424,"activeCount":99},[],{"intervention":426,"totalTrials":378,"cells":427},"Gemcitabine",{"EARLY_PHASE1":428,"PHASE1":430,"PHASE2":432,"PHASE3":460,"PHASE4":462,"NA":464},{"trials":429,"activeCount":99},[],{"trials":431,"activeCount":99},[],{"trials":433,"activeCount":95,"soonestReadout":438},[434,447],{"nctId":435,"briefTitle":436,"status":228,"phases":437,"primaryCompletion":438,"completion":439,"start":440,"enrollment":441,"conditions":442,"interventions":444},"NCT04241276","A Randomised Trial of ATRA in a Novel Drug Combination for Pancreatic Cancer",[88],"2028-06-29","2029-02-28","2020-04-30",170,[443],"Pancreatic Cancer",[445,426,446],"ATRA","nab-paclitaxel",{"nctId":448,"briefTitle":449,"status":450,"phases":451,"primaryCompletion":452,"completion":453,"start":454,"enrollment":455,"conditions":456,"interventions":458},"NCT02423590","Study of Gemcitabine\u002FCarboplatin First-line Chemotherapy +\u002F- Apatorsen in Advanced Squamous Cell Lung Cancers","UNKNOWN",[88],"2018-05","2018-06","2014-06",140,[457],"Squamous Cell Lung Cancer",[459,426,343],"Apatorsen",{"trials":461,"activeCount":99},[],{"trials":463,"activeCount":99},[],{"trials":465,"activeCount":99},[],{"intervention":354,"totalTrials":378,"cells":467},{"EARLY_PHASE1":468,"PHASE1":470,"PHASE2":472,"PHASE3":482,"PHASE4":484,"NA":486},{"trials":469,"activeCount":99},[],{"trials":471,"activeCount":99},[],{"trials":473,"activeCount":95,"soonestReadout":59},[474,478],{"nctId":57,"briefTitle":58,"status":228,"phases":475,"primaryCompletion":59,"completion":59,"start":349,"enrollment":350,"conditions":476,"interventions":477},[88],[352],[50,354,355,356,357],{"nctId":359,"briefTitle":360,"status":361,"phases":479,"primaryCompletion":363,"completion":363,"start":364,"enrollment":365,"conditions":480,"interventions":481},[88],[20,367],[50,369,354,370],{"trials":483,"activeCount":99},[],{"trials":485,"activeCount":99},[],{"trials":487,"activeCount":99},[],{"intervention":69,"totalTrials":95,"cells":489},{"EARLY_PHASE1":490,"PHASE1":492,"PHASE2":494,"PHASE3":504,"PHASE4":506,"NA":508},{"trials":491,"activeCount":99},[],{"trials":493,"activeCount":99},[],{"trials":495,"activeCount":95,"soonestReadout":68},[496],{"nctId":66,"briefTitle":67,"status":109,"phases":497,"primaryCompletion":68,"completion":498,"start":499,"enrollment":500,"conditions":501,"interventions":503},[88],"2027-12-22","2021-12-16",320,[502],"Urinary Bladder Neoplasms",[69],{"trials":505,"activeCount":99},[],{"trials":507,"activeCount":99},[],{"trials":509,"activeCount":99},[],{"intervention":84,"totalTrials":95,"cells":511},{"EARLY_PHASE1":512,"PHASE1":514,"PHASE2":516,"PHASE3":525,"PHASE4":527,"NA":529},{"trials":513,"activeCount":99},[],{"trials":515,"activeCount":99},[],{"trials":517,"activeCount":95,"soonestReadout":83},[518],{"nctId":81,"briefTitle":82,"status":109,"phases":519,"primaryCompletion":83,"completion":83,"start":520,"enrollment":521,"conditions":522,"interventions":524},[88],"2022-12-01",40,[18,523],"Clinically Isolated Syndrome of Demyelination",[84],{"trials":526,"activeCount":99},[],{"trials":528,"activeCount":99},[],{"trials":530,"activeCount":99},[],{"intervention":445,"totalTrials":95,"cells":532},{"EARLY_PHASE1":533,"PHASE1":535,"PHASE2":537,"PHASE3":543,"PHASE4":545,"NA":547},{"trials":534,"activeCount":99},[],{"trials":536,"activeCount":99},[],{"trials":538,"activeCount":95,"soonestReadout":438},[539],{"nctId":435,"briefTitle":436,"status":228,"phases":540,"primaryCompletion":438,"completion":439,"start":440,"enrollment":441,"conditions":541,"interventions":542},[88],[443],[445,426,446],{"trials":544,"activeCount":99},[],{"trials":546,"activeCount":99},[],{"trials":548,"activeCount":99},[],{"intervention":446,"totalTrials":95,"cells":550},{"EARLY_PHASE1":551,"PHASE1":553,"PHASE2":555,"PHASE3":561,"PHASE4":563,"NA":565},{"trials":552,"activeCount":99},[],{"trials":554,"activeCount":99},[],{"trials":556,"activeCount":95,"soonestReadout":438},[557],{"nctId":435,"briefTitle":436,"status":228,"phases":558,"primaryCompletion":438,"completion":439,"start":440,"enrollment":441,"conditions":559,"interventions":560},[88],[443],[445,426,446],{"trials":562,"activeCount":99},[],{"trials":564,"activeCount":99},[],{"trials":566,"activeCount":99},[],{"intervention":568,"totalTrials":95,"cells":569},"Continue rivaroxaban or apixaban or warfarin",{"EARLY_PHASE1":570,"PHASE1":572,"PHASE2":574,"PHASE3":588,"PHASE4":590,"NA":592},{"trials":571,"activeCount":99},[],{"trials":573,"activeCount":99},[],{"trials":575,"activeCount":95,"soonestReadout":581},[576],{"nctId":577,"briefTitle":578,"status":579,"phases":580,"primaryCompletion":581,"completion":581,"start":582,"enrollment":583,"conditions":584,"interventions":586},"NCT07246005","LVT DURATION: Pilot Study of Anticoagulation Duration for Left Ventricular Thrombus","NOT_YET_RECRUITING",[88],"2027-12-01","2026-12-01",120,[585],"Left Ventricular Thrombus",[568,587],"Discontinue rivaroxaban or apixaban or warfarin",{"trials":589,"activeCount":99},[],{"trials":591,"activeCount":99},[],{"trials":593,"activeCount":99},[],{"intervention":587,"totalTrials":95,"cells":595},{"EARLY_PHASE1":596,"PHASE1":598,"PHASE2":600,"PHASE3":606,"PHASE4":608,"NA":610},{"trials":597,"activeCount":99},[],{"trials":599,"activeCount":99},[],{"trials":601,"activeCount":95,"soonestReadout":581},[602],{"nctId":577,"briefTitle":578,"status":579,"phases":603,"primaryCompletion":581,"completion":581,"start":582,"enrollment":583,"conditions":604,"interventions":605},[88],[585],[568,587],{"trials":607,"activeCount":99},[],{"trials":609,"activeCount":99},[],{"trials":611,"activeCount":99},[],{"intervention":356,"totalTrials":95,"cells":613},{"EARLY_PHASE1":614,"PHASE1":616,"PHASE2":618,"PHASE3":624,"PHASE4":626,"NA":628},{"trials":615,"activeCount":99},[],{"trials":617,"activeCount":99},[],{"trials":619,"activeCount":95,"soonestReadout":59},[620],{"nctId":57,"briefTitle":58,"status":228,"phases":621,"primaryCompletion":59,"completion":59,"start":349,"enrollment":350,"conditions":622,"interventions":623},[88],[352],[50,354,355,356,357],{"trials":625,"activeCount":99},[],{"trials":627,"activeCount":99},[],{"trials":629,"activeCount":99},[],{"intervention":357,"totalTrials":95,"cells":631},{"EARLY_PHASE1":632,"PHASE1":634,"PHASE2":636,"PHASE3":642,"PHASE4":644,"NA":646},{"trials":633,"activeCount":99},[],{"trials":635,"activeCount":99},[],{"trials":637,"activeCount":95,"soonestReadout":59},[638],{"nctId":57,"briefTitle":58,"status":228,"phases":639,"primaryCompletion":59,"completion":59,"start":349,"enrollment":350,"conditions":640,"interventions":641},[88],[352],[50,354,355,356,357],{"trials":643,"activeCount":99},[],{"trials":645,"activeCount":99},[],{"trials":647,"activeCount":99},[],{"intervention":649,"totalTrials":95,"cells":650},"Datopotamab Deruxtecan",{"EARLY_PHASE1":651,"PHASE1":653,"PHASE2":655,"PHASE3":667,"PHASE4":669,"NA":671},{"trials":652,"activeCount":99},[],{"trials":654,"activeCount":99},[],{"trials":656,"activeCount":95,"soonestReadout":661},[657],{"nctId":658,"briefTitle":659,"status":109,"phases":660,"primaryCompletion":661,"completion":662,"start":663,"enrollment":455,"conditions":664,"interventions":665},"NCT06954480","Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer",[88],"2028-02","2030-02","2025-10-27",[352],[649,666],"Durvalumab",{"trials":668,"activeCount":99},[],{"trials":670,"activeCount":99},[],{"trials":672,"activeCount":99},[],{"intervention":666,"totalTrials":95,"cells":674},{"EARLY_PHASE1":675,"PHASE1":677,"PHASE2":679,"PHASE3":685,"PHASE4":687,"NA":689},{"trials":676,"activeCount":99},[],{"trials":678,"activeCount":99},[],{"trials":680,"activeCount":95,"soonestReadout":661},[681],{"nctId":658,"briefTitle":659,"status":109,"phases":682,"primaryCompletion":661,"completion":662,"start":663,"enrollment":455,"conditions":683,"interventions":684},[88],[352],[649,666],{"trials":686,"activeCount":99},[],{"trials":688,"activeCount":99},[],{"trials":690,"activeCount":99},[],{"intervention":45,"totalTrials":95,"cells":692},{"EARLY_PHASE1":693,"PHASE1":695,"PHASE2":706,"PHASE3":708,"PHASE4":710,"NA":712},{"trials":694,"activeCount":99},[],{"trials":696,"activeCount":95,"soonestReadout":44},[697],{"nctId":42,"briefTitle":43,"status":228,"phases":698,"primaryCompletion":44,"completion":44,"start":699,"enrollment":700,"conditions":701,"interventions":703},[87],"2021-05-10",98,[15,702],"Endothelial Dysfunction",[45,704,705],"Concentrate beetroot Juice","Nitrate-deplete beetroot juice",{"trials":707,"activeCount":99},[],{"trials":709,"activeCount":99},[],{"trials":711,"activeCount":99},[],{"trials":713,"activeCount":99},[],{"intervention":704,"totalTrials":95,"cells":715},{"EARLY_PHASE1":716,"PHASE1":718,"PHASE2":724,"PHASE3":726,"PHASE4":728,"NA":730},{"trials":717,"activeCount":99},[],{"trials":719,"activeCount":95,"soonestReadout":44},[720],{"nctId":42,"briefTitle":43,"status":228,"phases":721,"primaryCompletion":44,"completion":44,"start":699,"enrollment":700,"conditions":722,"interventions":723},[87],[15,702],[45,704,705],{"trials":725,"activeCount":99},[],{"trials":727,"activeCount":99},[],{"trials":729,"activeCount":99},[],{"trials":731,"activeCount":99},[],{"intervention":705,"totalTrials":95,"cells":733},{"EARLY_PHASE1":734,"PHASE1":736,"PHASE2":742,"PHASE3":744,"PHASE4":746,"NA":748},{"trials":735,"activeCount":99},[],{"trials":737,"activeCount":95,"soonestReadout":44},[738],{"nctId":42,"briefTitle":43,"status":228,"phases":739,"primaryCompletion":44,"completion":44,"start":699,"enrollment":700,"conditions":740,"interventions":741},[87],[15,702],[45,704,705],{"trials":743,"activeCount":99},[],{"trials":745,"activeCount":99},[],{"trials":747,"activeCount":99},[],{"trials":749,"activeCount":99},[],{"intervention":751,"totalTrials":378,"cells":752},"Cantharidin",{"EARLY_PHASE1":753,"PHASE1":777,"PHASE2":779,"PHASE3":781,"PHASE4":783,"NA":785},{"trials":754,"activeCount":95,"soonestReadout":759},[755,765],{"nctId":756,"briefTitle":757,"status":109,"phases":758,"primaryCompletion":759,"completion":759,"start":760,"enrollment":761,"conditions":762,"interventions":764},"NCT05597098","Investigation of the Distinct Mechanisms Involved in Inflammatory Resolution Between Healthy Men and Women",[86],"2027-12-12","2022-12-12",34,[763],"Inflammation",[751],{"nctId":766,"briefTitle":767,"status":361,"phases":768,"primaryCompletion":769,"completion":770,"start":771,"enrollment":772,"conditions":773,"interventions":775},"NCT01582321","Investigation of the Influence of Gender on Cardiovascular Function",[86],"2016-12","2017-01","2012-03",56,[774],"Cardiovascular Function",[776,751],"Typhoid vaccine",{"trials":778,"activeCount":99},[],{"trials":780,"activeCount":99},[],{"trials":782,"activeCount":99},[],{"trials":784,"activeCount":99},[],{"trials":786,"activeCount":99},[],{"intervention":788,"totalTrials":95,"cells":789},"Hyaluronic Acid (HA) and Octenidine gel",{"EARLY_PHASE1":790,"PHASE1":792,"PHASE2":794,"PHASE3":796,"PHASE4":798,"NA":800},{"trials":791,"activeCount":99},[],{"trials":793,"activeCount":99},[],{"trials":795,"activeCount":99},[],{"trials":797,"activeCount":99},[],{"trials":799,"activeCount":99},[],{"trials":801,"activeCount":95,"soonestReadout":314},[802],{"nctId":803,"briefTitle":804,"status":109,"phases":805,"primaryCompletion":314,"completion":314,"start":806,"enrollment":807,"conditions":808,"interventions":812},"NCT06522438","Hyaluronic Acid and Octenidine Gel as an Adjunct to Non-surgical Periodontal Treatment",[91],"2025-06-03",26,[30,33,809,810,811],"Periodontal Pocket","Periodontal Inflammation","Periodontal Attachment Loss",[788],{"intervention":64,"totalTrials":95,"cells":814},{"EARLY_PHASE1":815,"PHASE1":817,"PHASE2":819,"PHASE3":821,"PHASE4":823,"NA":825},{"trials":816,"activeCount":99},[],{"trials":818,"activeCount":99},[],{"trials":820,"activeCount":99},[],{"trials":822,"activeCount":99},[],{"trials":824,"activeCount":99},[],{"trials":826,"activeCount":95,"soonestReadout":63},[827],{"nctId":61,"briefTitle":62,"status":109,"phases":828,"primaryCompletion":63,"completion":63,"start":829,"enrollment":830,"conditions":831,"interventions":833},[91],"2024-10-21",24,[832,33,810,809,811],"Periodontal Diseases",[64],{"intervention":74,"totalTrials":95,"cells":835},{"EARLY_PHASE1":836,"PHASE1":838,"PHASE2":840,"PHASE3":842,"PHASE4":844,"NA":846},{"trials":837,"activeCount":99},[],{"trials":839,"activeCount":99},[],{"trials":841,"activeCount":99},[],{"trials":843,"activeCount":99},[],{"trials":845,"activeCount":99},[],{"trials":847,"activeCount":95,"soonestReadout":73},[848],{"nctId":71,"briefTitle":72,"status":849,"phases":850,"primaryCompletion":73,"completion":851,"start":852,"enrollment":853,"conditions":854,"interventions":856},"ENROLLING_BY_INVITATION",[91],"2027-09","2023-06-01",318,[855],"Hepatitis C",[74],{"intervention":40,"totalTrials":95,"cells":858},{"EARLY_PHASE1":859,"PHASE1":861,"PHASE2":863,"PHASE3":865,"PHASE4":867,"NA":869},{"trials":860,"activeCount":99},[],{"trials":862,"activeCount":99},[],{"trials":864,"activeCount":99},[],{"trials":866,"activeCount":99},[],{"trials":868,"activeCount":99},[],{"trials":870,"activeCount":95,"soonestReadout":39},[871],{"nctId":37,"briefTitle":38,"status":228,"phases":872,"primaryCompletion":39,"completion":873,"start":874,"enrollment":875,"conditions":876,"interventions":878},[91],"2026-06-15","2023-03-21",48,[877],"Acute Respiratory Distress Syndrome",[40],{"intervention":880,"totalTrials":95,"cells":881},"Patients in hospitals allocated to this arm will receive aspirin as their routine thromboprophylaxis after surgery.",{"EARLY_PHASE1":882,"PHASE1":884,"PHASE2":886,"PHASE3":888,"PHASE4":890,"NA":892},{"trials":883,"activeCount":99},[],{"trials":885,"activeCount":99},[],{"trials":887,"activeCount":99},[],{"trials":889,"activeCount":99},[],{"trials":891,"activeCount":99},[],{"trials":893,"activeCount":95,"soonestReadout":83},[894],{"nctId":895,"briefTitle":896,"status":579,"phases":897,"primaryCompletion":83,"completion":898,"start":899,"enrollment":900,"conditions":901,"interventions":904},"NCT06937372","Delivery and Implementation of a Randomised Crossover Trial on Thrombosis",[91],"2028-04-30","2026-08-01",21194,[902,903],"Hip Fractures","Venous Thromboembolism (VTE)",[880,905],"Low molecular weight heparin",{"intervention":905,"totalTrials":95,"cells":907},{"EARLY_PHASE1":908,"PHASE1":910,"PHASE2":912,"PHASE3":914,"PHASE4":916,"NA":918},{"trials":909,"activeCount":99},[],{"trials":911,"activeCount":99},[],{"trials":913,"activeCount":99},[],{"trials":915,"activeCount":99},[],{"trials":917,"activeCount":99},[],{"trials":919,"activeCount":95,"soonestReadout":83},[920],{"nctId":895,"briefTitle":896,"status":579,"phases":921,"primaryCompletion":83,"completion":898,"start":899,"enrollment":900,"conditions":922,"interventions":923},[91],[902,903],[880,905],{"intervention":79,"totalTrials":95,"cells":925},{"EARLY_PHASE1":926,"PHASE1":928,"PHASE2":930,"PHASE3":932,"PHASE4":934,"NA":936},{"trials":927,"activeCount":99},[],{"trials":929,"activeCount":99},[],{"trials":931,"activeCount":99},[],{"trials":933,"activeCount":99},[],{"trials":935,"activeCount":99},[],{"trials":937,"activeCount":95,"soonestReadout":78},[938],{"nctId":76,"briefTitle":77,"status":109,"phases":939,"primaryCompletion":78,"completion":78,"start":940,"enrollment":941,"conditions":942,"interventions":944},[],"2021-07-26",25600,[943],"Inflammatory Bowel Diseases",[79,945,79],"Assessment of Genetics",{"intervention":945,"totalTrials":95,"cells":947},{"EARLY_PHASE1":948,"PHASE1":950,"PHASE2":952,"PHASE3":954,"PHASE4":956,"NA":958},{"trials":949,"activeCount":99},[],{"trials":951,"activeCount":99},[],{"trials":953,"activeCount":99},[],{"trials":955,"activeCount":99},[],{"trials":957,"activeCount":99},[],{"trials":959,"activeCount":95,"soonestReadout":78},[960],{"nctId":76,"briefTitle":77,"status":109,"phases":961,"primaryCompletion":78,"completion":78,"start":940,"enrollment":941,"conditions":962,"interventions":963},[],[943],[79,945,79],{"intervention":965,"totalTrials":95,"cells":966},"Genetic testing for Cancer Susceptibility Genes (CSGs) (BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2, MLH1, MSH2, MSH6) and personalised breast and ovarian cancer risk",{"EARLY_PHASE1":967,"PHASE1":969,"PHASE2":971,"PHASE3":973,"PHASE4":975,"NA":977},{"trials":968,"activeCount":99},[],{"trials":970,"activeCount":99},[],{"trials":972,"activeCount":99},[],{"trials":974,"activeCount":99},[],{"trials":976,"activeCount":99},[],{"trials":978,"activeCount":95,"soonestReadout":983},[979],{"nctId":980,"briefTitle":981,"status":109,"phases":982,"primaryCompletion":983,"completion":984,"start":985,"enrollment":986,"conditions":987,"interventions":991},"NCT07498829","Population Based Germline Testing for Early Detection and Prevention of Cancer",[91],"2029-12","2040-12","2025-12-18",6000,[988,989,990],"Breast Cancer Risk","Ovarian Cancer Risk","Cancer Gene Mutation",[965],{"intervention":993,"totalTrials":95,"cells":994},"Carboplatin AUC10",{"EARLY_PHASE1":995,"PHASE1":997,"PHASE2":999,"PHASE3":1001,"PHASE4":1003,"NA":1005},{"trials":996,"activeCount":99},[],{"trials":998,"activeCount":99},[],{"trials":1000,"activeCount":99},[],{"trials":1002,"activeCount":99},[],{"trials":1004,"activeCount":99},[],{"trials":1006,"activeCount":95,"soonestReadout":1011},[1007],{"nctId":1008,"briefTitle":1009,"status":109,"phases":1010,"primaryCompletion":1011,"completion":1011,"start":1012,"enrollment":1013,"conditions":1014,"interventions":1016},"NCT06309745","THERApy De-escalation for TESTicular Cancer",[],"2028-10-02","2024-06-24",30,[1015],"Seminoma",[993],{"intervention":1018,"totalTrials":378,"cells":1019},"Amlodipine",{"EARLY_PHASE1":1020,"PHASE1":1022,"PHASE2":1024,"PHASE3":1026,"PHASE4":1028,"NA":1049},{"trials":1021,"activeCount":99},[],{"trials":1023,"activeCount":99},[],{"trials":1025,"activeCount":99},[],{"trials":1027,"activeCount":99},[],{"trials":1029,"activeCount":99},[1030,1040],{"nctId":1031,"briefTitle":1032,"status":361,"phases":1033,"primaryCompletion":1034,"completion":1035,"start":1036,"enrollment":1037,"conditions":1038,"interventions":1039},"NCT04559074","Personalised Electronic Record Supported Optimisation When Alone for Patients With Hypertension",[90],"2021-11-10","2021-11-19","2020-10-23",343,[22],[1018],{"nctId":1041,"briefTitle":1042,"status":334,"phases":1043,"primaryCompletion":1044,"completion":1045,"start":1046,"enrollment":99,"conditions":1047,"interventions":1048},"NCT06713785","Personalised Electronic Record Supported Optimisation of Amlodipine for Patients With Hypertension",[90],"2021-01-31","2021-05-31","2020-09-26",[22],[1018],{"trials":1050,"activeCount":99},[],{"intervention":1052,"totalTrials":95,"cells":1053},"Ferrous sulphate",{"EARLY_PHASE1":1054,"PHASE1":1056,"PHASE2":1058,"PHASE3":1060,"PHASE4":1062,"NA":1075},{"trials":1055,"activeCount":99},[],{"trials":1057,"activeCount":99},[],{"trials":1059,"activeCount":99},[],{"trials":1061,"activeCount":99},[],{"trials":1063,"activeCount":99},[1064],{"nctId":1065,"briefTitle":1066,"status":361,"phases":1067,"primaryCompletion":1068,"completion":1068,"start":1069,"enrollment":1070,"conditions":1071,"interventions":1074},"NCT01991314","Treatment of Iron Deficiency Anaemia in Inflammatory Bowel Disease With Ferrous Sulphate",[90],"2015-06","2011-12",90,[1072,1073],"Ulcerative Colitis","Crohn's Disease",[1052],{"trials":1076,"activeCount":99},[],{"intervention":1078,"totalTrials":95,"cells":1079},"5- fluorouracil",{"EARLY_PHASE1":1080,"PHASE1":1082,"PHASE2":1084,"PHASE3":1086,"PHASE4":1088,"NA":1098},{"trials":1081,"activeCount":99},[],{"trials":1083,"activeCount":99},[],{"trials":1085,"activeCount":99},[],{"trials":1087,"activeCount":99},[],{"trials":1089,"activeCount":99},[1090],{"nctId":1091,"briefTitle":1092,"status":334,"phases":1093,"enrollment":99,"conditions":1094,"interventions":1096},"NCT01295099","Keloid Scarring: Treatment and Pathophysiology",[90],[1095],"Keloid Scar",[1078,1097],"Triamcinolone",{"trials":1099,"activeCount":99},[],{"intervention":1097,"totalTrials":95,"cells":1101},{"EARLY_PHASE1":1102,"PHASE1":1104,"PHASE2":1106,"PHASE3":1108,"PHASE4":1110,"NA":1116},{"trials":1103,"activeCount":99},[],{"trials":1105,"activeCount":99},[],{"trials":1107,"activeCount":99},[],{"trials":1109,"activeCount":99},[],{"trials":1111,"activeCount":99},[1112],{"nctId":1091,"briefTitle":1092,"status":334,"phases":1113,"enrollment":99,"conditions":1114,"interventions":1115},[90],[1095],[1078,1097],{"trials":1117,"activeCount":99},[],{"intervention":1119,"totalTrials":95,"cells":1120},"Fluticasone 500mcg BD via accuhaler or identical placebo",{"EARLY_PHASE1":1121,"PHASE1":1123,"PHASE2":1125,"PHASE3":1127,"PHASE4":1129,"NA":1141},{"trials":1122,"activeCount":99},[],{"trials":1124,"activeCount":99},[],{"trials":1126,"activeCount":99},[],{"trials":1128,"activeCount":99},[],{"trials":1130,"activeCount":99},[1131],{"nctId":1132,"briefTitle":1133,"status":361,"phases":1134,"completion":1135,"start":1136,"enrollment":1137,"conditions":1138,"interventions":1140},"NCT00440687","Withdrawal of Inhaled Corticosteroids in Patients With COPD in Primary Care",[90],"2004-03","2001-01",256,[1139],"Chronic Obstructive Pulmonary Disease",[1119],{"trials":1142,"activeCount":99},[],{"intervention":1144,"totalTrials":95,"cells":1145},"Telaprevir",{"EARLY_PHASE1":1146,"PHASE1":1148,"PHASE2":1150,"PHASE3":1152,"PHASE4":1154,"NA":1167},{"trials":1147,"activeCount":99},[],{"trials":1149,"activeCount":99},[],{"trials":1151,"activeCount":99},[],{"trials":1153,"activeCount":99},[],{"trials":1155,"activeCount":99},[1156],{"nctId":1157,"briefTitle":1158,"status":361,"phases":1159,"primaryCompletion":1160,"completion":1160,"start":1161,"enrollment":1162,"conditions":1163,"interventions":1164},"NCT02087111","Telaprevir in Genotype 3 HCV",[90],"2016-11-01","2014-04",14,[855],[1144,1165,1166],"40 Kd Pegylated interferon alfa 2a","Ribavirin",{"trials":1168,"activeCount":99},[],{"intervention":1165,"totalTrials":95,"cells":1170},{"EARLY_PHASE1":1171,"PHASE1":1173,"PHASE2":1175,"PHASE3":1177,"PHASE4":1179,"NA":1185},{"trials":1172,"activeCount":99},[],{"trials":1174,"activeCount":99},[],{"trials":1176,"activeCount":99},[],{"trials":1178,"activeCount":99},[],{"trials":1180,"activeCount":99},[1181],{"nctId":1157,"briefTitle":1158,"status":361,"phases":1182,"primaryCompletion":1160,"completion":1160,"start":1161,"enrollment":1162,"conditions":1183,"interventions":1184},[90],[855],[1144,1165,1166],{"trials":1186,"activeCount":99},[],{"intervention":1166,"totalTrials":95,"cells":1188},{"EARLY_PHASE1":1189,"PHASE1":1191,"PHASE2":1193,"PHASE3":1195,"PHASE4":1197,"NA":1203},{"trials":1190,"activeCount":99},[],{"trials":1192,"activeCount":99},[],{"trials":1194,"activeCount":99},[],{"trials":1196,"activeCount":99},[],{"trials":1198,"activeCount":99},[1199],{"nctId":1157,"briefTitle":1158,"status":361,"phases":1200,"primaryCompletion":1160,"completion":1160,"start":1161,"enrollment":1162,"conditions":1201,"interventions":1202},[90],[855],[1144,1165,1166],{"trials":1204,"activeCount":99},[],{"intervention":1206,"totalTrials":386,"cells":1207},"Varenicline",{"EARLY_PHASE1":1208,"PHASE1":1210,"PHASE2":1212,"PHASE3":1214,"PHASE4":1247,"NA":1249},{"trials":1209,"activeCount":99},[],{"trials":1211,"activeCount":99},[],{"trials":1213,"activeCount":99},[],{"trials":1215,"activeCount":99},[1216,1227,1237],{"nctId":1217,"briefTitle":1218,"status":361,"phases":1219,"primaryCompletion":1220,"completion":1221,"start":1222,"enrollment":1223,"conditions":1224,"interventions":1226},"NCT01206010","Tailoring Varenicline to Individual Needs (TVIN Study)",[89],"2012-11","2013-02","2011-07",200,[1225,25],"Tobacco Dependence",[1206,1206],{"nctId":1228,"briefTitle":1229,"status":361,"phases":1230,"primaryCompletion":1231,"completion":1232,"start":1233,"enrollment":1234,"conditions":1235,"interventions":1236},"NCT00789074","Use of Varenicline for 4-weeks Prior to Quitting",[89],"2009-12","2010-03","2009-07",101,[1225,25],[1206],{"nctId":1238,"briefTitle":1239,"status":361,"phases":1240,"primaryCompletion":1241,"completion":1241,"start":1242,"enrollment":1243,"conditions":1244,"interventions":1245},"NCT01184664","Combination of Nicotine Replacement Therapy (NRT) and Varenicline to Increase Cessation of Tobacco (CONVICT Study)",[89],"2011-10","2011-04",117,[1225,25],[1246,1206],"Nicotine Patch",{"trials":1248,"activeCount":99},[],{"trials":1250,"activeCount":99},[],{"intervention":1252,"totalTrials":378,"cells":1253},"cisplatin",{"EARLY_PHASE1":1254,"PHASE1":1256,"PHASE2":1258,"PHASE3":1277,"PHASE4":1292,"NA":1294},{"trials":1255,"activeCount":99},[],{"trials":1257,"activeCount":99},[],{"trials":1259,"activeCount":99},[1260],{"nctId":1261,"briefTitle":1262,"status":361,"phases":1263,"primaryCompletion":1264,"completion":1265,"start":1266,"enrollment":1267,"conditions":1268,"interventions":1270},"NCT06309732","GAMEC-II, Risk-adapted Protocol for Relapsed Germ Cell Tumours (GCT)",[88],"2013-06","2014-01","2006-07",36,[1269],"Testicular Neoplasms",[1271,1272,1273,1274,1275,1276],"Pegfilgrastim","Dactinomycin","Methotrexate","Etoposide","Cisplatin","Epirubicin",{"trials":1278,"activeCount":99},[1279],{"nctId":1280,"briefTitle":1281,"status":361,"phases":1282,"completion":1283,"start":1284,"enrollment":1285,"conditions":1286,"interventions":1289},"NCT00324298","Bleomycin, Etoposide, and Cisplatin in Treating Patients With Metastatic Germ Cell Cancer of the Testicles",[89],"2011-03","2003-07",210,[1287,1288],"Drug\u002FAgent Toxicity by Tissue\u002FOrgan","Testicular Germ Cell Tumor",[1290,1252,1291],"bleomycin sulfate","etoposide",{"trials":1293,"activeCount":99},[],{"trials":1295,"activeCount":99},[],{"intervention":1291,"totalTrials":378,"cells":1297},{"EARLY_PHASE1":1298,"PHASE1":1300,"PHASE2":1302,"PHASE3":1308,"PHASE4":1314,"NA":1316},{"trials":1299,"activeCount":99},[],{"trials":1301,"activeCount":99},[],{"trials":1303,"activeCount":99},[1304],{"nctId":1261,"briefTitle":1262,"status":361,"phases":1305,"primaryCompletion":1264,"completion":1265,"start":1266,"enrollment":1267,"conditions":1306,"interventions":1307},[88],[1269],[1271,1272,1273,1274,1275,1276],{"trials":1309,"activeCount":99},[1310],{"nctId":1280,"briefTitle":1281,"status":361,"phases":1311,"completion":1283,"start":1284,"enrollment":1285,"conditions":1312,"interventions":1313},[89],[1287,1288],[1290,1252,1291],{"trials":1315,"activeCount":99},[],{"trials":1317,"activeCount":99},[],{"intervention":1319,"totalTrials":378,"cells":1320},"anastrozole",{"EARLY_PHASE1":1321,"PHASE1":1323,"PHASE2":1325,"PHASE3":1327,"PHASE4":1348,"NA":1350},{"trials":1322,"activeCount":99},[],{"trials":1324,"activeCount":99},[],{"trials":1326,"activeCount":99},[],{"trials":1328,"activeCount":99},[1329,1338],{"nctId":1330,"briefTitle":1331,"status":361,"phases":1332,"primaryCompletion":1333,"completion":1045,"start":1334,"enrollment":1335,"conditions":1336,"interventions":1337},"NCT00078832","Anastrozole in Preventing Breast Cancer in Postmenopausal Women at Increased Risk of Breast Cancer",[89],"2013-12","2003-09",3864,[20],[1319],{"nctId":1339,"briefTitle":1340,"status":361,"phases":1341,"primaryCompletion":1342,"completion":1045,"start":1334,"enrollment":1343,"conditions":1344,"interventions":1345},"NCT00072462","Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ",[89],"2015-12",2980,[20],[1346,1347],"tamoxifen citrate","Anastrozole",{"trials":1349,"activeCount":99},[],{"trials":1351,"activeCount":99},[],{"intervention":1290,"totalTrials":95,"cells":1353},{"EARLY_PHASE1":1354,"PHASE1":1356,"PHASE2":1358,"PHASE3":1360,"PHASE4":1366,"NA":1368},{"trials":1355,"activeCount":99},[],{"trials":1357,"activeCount":99},[],{"trials":1359,"activeCount":99},[],{"trials":1361,"activeCount":99},[1362],{"nctId":1280,"briefTitle":1281,"status":361,"phases":1363,"completion":1283,"start":1284,"enrollment":1285,"conditions":1364,"interventions":1365},[89],[1287,1288],[1290,1252,1291],{"trials":1367,"activeCount":99},[],{"trials":1369,"activeCount":99},[],{"intervention":1371,"totalTrials":95,"cells":1372},"High dose Aspirin & Vitamin D",{"EARLY_PHASE1":1373,"PHASE1":1375,"PHASE2":1377,"PHASE3":1379,"PHASE4":1395,"NA":1397},{"trials":1374,"activeCount":99},[],{"trials":1376,"activeCount":99},[],{"trials":1378,"activeCount":99},[],{"trials":1380,"activeCount":99},[1381],{"nctId":1382,"briefTitle":1383,"status":361,"phases":1384,"primaryCompletion":1385,"completion":1385,"start":769,"enrollment":1386,"conditions":1387,"interventions":1389},"NCT03103152","A Study to Examine the Effectiveness of Aspirin and\u002For Vitamin D3 to Prevent Prostate Cancer Progression",[88,89],"2020-03-31",104,[1388],"Prostate Cancer",[1371,1390,1391,1392,1393,1394],"High dose Aspirin, Vitamin D placebo","Low dose Aspirin , Vitamin D","Low dose Aspirin, Vitamin D placebo","Aspirin Placebo, Vitamin D","Aspirin placebo, Vitamin D placebo",{"trials":1396,"activeCount":99},[],{"trials":1398,"activeCount":99},[],{"intervention":1390,"totalTrials":95,"cells":1400},{"EARLY_PHASE1":1401,"PHASE1":1403,"PHASE2":1405,"PHASE3":1407,"PHASE4":1413,"NA":1415},{"trials":1402,"activeCount":99},[],{"trials":1404,"activeCount":99},[],{"trials":1406,"activeCount":99},[],{"trials":1408,"activeCount":99},[1409],{"nctId":1382,"briefTitle":1383,"status":361,"phases":1410,"primaryCompletion":1385,"completion":1385,"start":769,"enrollment":1386,"conditions":1411,"interventions":1412},[88,89],[1388],[1371,1390,1391,1392,1393,1394],{"trials":1414,"activeCount":99},[],{"trials":1416,"activeCount":99},[],{"intervention":1391,"totalTrials":95,"cells":1418},{"EARLY_PHASE1":1419,"PHASE1":1421,"PHASE2":1423,"PHASE3":1425,"PHASE4":1431,"NA":1433},{"trials":1420,"activeCount":99},[],{"trials":1422,"activeCount":99},[],{"trials":1424,"activeCount":99},[],{"trials":1426,"activeCount":99},[1427],{"nctId":1382,"briefTitle":1383,"status":361,"phases":1428,"primaryCompletion":1385,"completion":1385,"start":769,"enrollment":1386,"conditions":1429,"interventions":1430},[88,89],[1388],[1371,1390,1391,1392,1393,1394],{"trials":1432,"activeCount":99},[],{"trials":1434,"activeCount":99},[],{"intervention":1392,"totalTrials":95,"cells":1436},{"EARLY_PHASE1":1437,"PHASE1":1439,"PHASE2":1441,"PHASE3":1443,"PHASE4":1449,"NA":1451},{"trials":1438,"activeCount":99},[],{"trials":1440,"activeCount":99},[],{"trials":1442,"activeCount":99},[],{"trials":1444,"activeCount":99},[1445],{"nctId":1382,"briefTitle":1383,"status":361,"phases":1446,"primaryCompletion":1385,"completion":1385,"start":769,"enrollment":1386,"conditions":1447,"interventions":1448},[88,89],[1388],[1371,1390,1391,1392,1393,1394],{"trials":1450,"activeCount":99},[],{"trials":1452,"activeCount":99},[],{"intervention":1393,"totalTrials":95,"cells":1454},{"EARLY_PHASE1":1455,"PHASE1":1457,"PHASE2":1459,"PHASE3":1461,"PHASE4":1467,"NA":1469},{"trials":1456,"activeCount":99},[],{"trials":1458,"activeCount":99},[],{"trials":1460,"activeCount":99},[],{"trials":1462,"activeCount":99},[1463],{"nctId":1382,"briefTitle":1383,"status":361,"phases":1464,"primaryCompletion":1385,"completion":1385,"start":769,"enrollment":1386,"conditions":1465,"interventions":1466},[88,89],[1388],[1371,1390,1391,1392,1393,1394],{"trials":1468,"activeCount":99},[],{"trials":1470,"activeCount":99},[],{"intervention":1394,"totalTrials":95,"cells":1472},{"EARLY_PHASE1":1473,"PHASE1":1475,"PHASE2":1477,"PHASE3":1479,"PHASE4":1485,"NA":1487},{"trials":1474,"activeCount":99},[],{"trials":1476,"activeCount":99},[],{"trials":1478,"activeCount":99},[],{"trials":1480,"activeCount":99},[1481],{"nctId":1382,"briefTitle":1383,"status":361,"phases":1482,"primaryCompletion":1385,"completion":1385,"start":769,"enrollment":1386,"conditions":1483,"interventions":1484},[88,89],[1388],[1371,1390,1391,1392,1393,1394],{"trials":1486,"activeCount":99},[],{"trials":1488,"activeCount":99},[],{"intervention":1246,"totalTrials":95,"cells":1490},{"EARLY_PHASE1":1491,"PHASE1":1493,"PHASE2":1495,"PHASE3":1497,"PHASE4":1503,"NA":1505},{"trials":1492,"activeCount":99},[],{"trials":1494,"activeCount":99},[],{"trials":1496,"activeCount":99},[],{"trials":1498,"activeCount":99},[1499],{"nctId":1238,"briefTitle":1239,"status":361,"phases":1500,"primaryCompletion":1241,"completion":1241,"start":1242,"enrollment":1243,"conditions":1501,"interventions":1502},[89],[1225,25],[1246,1206],{"trials":1504,"activeCount":99},[],{"trials":1506,"activeCount":99},[],{"intervention":1508,"totalTrials":95,"cells":1509},"lapatinib ditosylate",{"EARLY_PHASE1":1510,"PHASE1":1512,"PHASE2":1514,"PHASE3":1516,"PHASE4":1527,"NA":1529},{"trials":1511,"activeCount":99},[],{"trials":1513,"activeCount":99},[],{"trials":1515,"activeCount":99},[],{"trials":1517,"activeCount":99},[1518],{"nctId":1519,"briefTitle":1520,"status":450,"phases":1521,"primaryCompletion":1522,"start":1523,"enrollment":316,"conditions":1524,"interventions":1526},"NCT00949455","A Double Blind Randomised Study of Lapatinib and Placebo in Metastatic TCC of the Urothelium",[88,89],"2015-07","2009-03",[1525],"Bladder Cancer",[1508],{"trials":1528,"activeCount":99},[],{"trials":1530,"activeCount":99},[],{"intervention":1532,"totalTrials":95,"cells":1533},"Tamoxifen Citrate 20Mg Tab",{"EARLY_PHASE1":1534,"PHASE1":1536,"PHASE2":1538,"PHASE3":1540,"PHASE4":1551,"NA":1553},{"trials":1535,"activeCount":99},[],{"trials":1537,"activeCount":99},[],{"trials":1539,"activeCount":99},[],{"trials":1541,"activeCount":99},[1542],{"nctId":1543,"briefTitle":1544,"status":361,"phases":1545,"primaryCompletion":1136,"completion":1546,"start":1547,"enrollment":1548,"conditions":1549,"interventions":1550},"NCT00002644","Tamoxifen for the Prevention of Breast Cancer in High-Risk Women",[89],"2011-03-30","1994-01",7154,[20],[1532],{"trials":1552,"activeCount":99},[],{"trials":1554,"activeCount":99},[],{"intervention":1346,"totalTrials":95,"cells":1556},{"EARLY_PHASE1":1557,"PHASE1":1559,"PHASE2":1561,"PHASE3":1563,"PHASE4":1569,"NA":1571},{"trials":1558,"activeCount":99},[],{"trials":1560,"activeCount":99},[],{"trials":1562,"activeCount":99},[],{"trials":1564,"activeCount":99},[1565],{"nctId":1339,"briefTitle":1340,"status":361,"phases":1566,"primaryCompletion":1342,"completion":1045,"start":1334,"enrollment":1343,"conditions":1567,"interventions":1568},[89],[20],[1346,1347],{"trials":1570,"activeCount":99},[],{"trials":1572,"activeCount":99},[],{"intervention":1574,"totalTrials":95,"cells":1575},"Mannitol",{"EARLY_PHASE1":1576,"PHASE1":1578,"PHASE2":1580,"PHASE3":1582,"PHASE4":1595,"NA":1597},{"trials":1577,"activeCount":99},[],{"trials":1579,"activeCount":99},[],{"trials":1581,"activeCount":99},[],{"trials":1583,"activeCount":99},[1584],{"nctId":1585,"briefTitle":1586,"status":361,"phases":1587,"primaryCompletion":1588,"completion":1588,"start":1589,"enrollment":1590,"conditions":1591,"interventions":1593},"NCT01142505","Wheeze and Intermittent Treatment",[89],"2014-02","2010-11",1358,[1592],"Wheezing",[1574,1594],"Montelukast",{"trials":1596,"activeCount":99},[],{"trials":1598,"activeCount":99},[],{"intervention":1594,"totalTrials":95,"cells":1600},{"EARLY_PHASE1":1601,"PHASE1":1603,"PHASE2":1605,"PHASE3":1607,"PHASE4":1613,"NA":1615},{"trials":1602,"activeCount":99},[],{"trials":1604,"activeCount":99},[],{"trials":1606,"activeCount":99},[],{"trials":1608,"activeCount":99},[1609],{"nctId":1585,"briefTitle":1586,"status":361,"phases":1610,"primaryCompletion":1588,"completion":1588,"start":1589,"enrollment":1590,"conditions":1611,"interventions":1612},[89],[1592],[1574,1594],{"trials":1614,"activeCount":99},[],{"trials":1616,"activeCount":99},[],{"intervention":1618,"totalTrials":386,"cells":1619},"AZD2014",{"EARLY_PHASE1":1620,"PHASE1":1622,"PHASE2":1624,"PHASE3":1660,"PHASE4":1662,"NA":1664},{"trials":1621,"activeCount":99},[],{"trials":1623,"activeCount":99},[],{"trials":1625,"activeCount":99},[1626,1638,1648],{"nctId":1627,"briefTitle":1628,"status":1629,"phases":1630,"primaryCompletion":1631,"completion":1632,"start":1221,"enrollment":1633,"conditions":1634,"interventions":1636},"NCT01793636","A Study Comparing AZD2014 vs Everolimus in Patients With Metastatic Renal Cancer","TERMINATED",[88],"2014-05","2015-11",49,[1635],"Metastatic Clear Cell Renal Carcinoma",[1618,1637],"Everolimus",{"nctId":1639,"briefTitle":1640,"status":361,"phases":1641,"primaryCompletion":337,"completion":337,"start":1642,"enrollment":1643,"conditions":1644,"interventions":1646},"NCT02216786","A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer",[88],"2014-01-16",333,[1645],"Estrogen Receptor Positive Breast Cancer",[1618,1637,1647],"Fulvestrant",{"nctId":1649,"briefTitle":1650,"status":450,"phases":1651,"primaryCompletion":1652,"completion":1652,"start":1068,"enrollment":1653,"conditions":1654,"interventions":1658},"NCT02583542","A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers",[87,88],"2020-03",118,[1655,457,1656,1657],"Triple-Negative Breast Cancer","Non-squamous Cell Lung Cancer With KRAS Mutations","Non-squamous Cell Lung Cancer With Wild-type KRAS",[1618,1659],"AZD6244",{"trials":1661,"activeCount":99},[],{"trials":1663,"activeCount":99},[],{"trials":1665,"activeCount":99},[],{"intervention":1637,"totalTrials":386,"cells":1667},{"EARLY_PHASE1":1668,"PHASE1":1670,"PHASE2":1681,"PHASE3":1691,"PHASE4":1693,"NA":1695},{"trials":1669,"activeCount":99},[],{"trials":1671,"activeCount":99},[1672],{"nctId":1673,"briefTitle":1674,"status":361,"phases":1675,"primaryCompletion":1676,"completion":1676,"start":1242,"enrollment":9,"conditions":1677,"interventions":1679},"NCT01714765","Dose Escalation Study Investigating Everolimus and Dovitinib in Metastatic Clear Cell Renal Cancer",[87],"2012-10",[1678],"Metastatic Clear Cell Renal Cancer",[1680,1637],"Dovitinib",{"trials":1682,"activeCount":99},[1683,1687],{"nctId":1627,"briefTitle":1628,"status":1629,"phases":1684,"primaryCompletion":1631,"completion":1632,"start":1221,"enrollment":1633,"conditions":1685,"interventions":1686},[88],[1635],[1618,1637],{"nctId":1639,"briefTitle":1640,"status":361,"phases":1688,"primaryCompletion":337,"completion":337,"start":1642,"enrollment":1643,"conditions":1689,"interventions":1690},[88],[1645],[1618,1637,1647],{"trials":1692,"activeCount":99},[],{"trials":1694,"activeCount":99},[],{"trials":1696,"activeCount":99},[],{"intervention":343,"totalTrials":378,"cells":1698},{"EARLY_PHASE1":1699,"PHASE1":1701,"PHASE2":1707,"PHASE3":1713,"PHASE4":1715,"NA":1717},{"trials":1700,"activeCount":99},[],{"trials":1702,"activeCount":99},[1703],{"nctId":332,"briefTitle":333,"status":334,"phases":1704,"primaryCompletion":336,"completion":337,"start":338,"enrollment":99,"conditions":1705,"interventions":1706},[87],[340],[50,342,343,344],{"trials":1708,"activeCount":99},[1709],{"nctId":448,"briefTitle":449,"status":450,"phases":1710,"primaryCompletion":452,"completion":453,"start":454,"enrollment":455,"conditions":1711,"interventions":1712},[88],[457],[459,426,343],{"trials":1714,"activeCount":99},[],{"trials":1716,"activeCount":99},[],{"trials":1718,"activeCount":99},[],{"intervention":1720,"totalTrials":95,"cells":1721},"Raltegravir",{"EARLY_PHASE1":1722,"PHASE1":1724,"PHASE2":1726,"PHASE3":1738,"PHASE4":1740,"NA":1742},{"trials":1723,"activeCount":99},[],{"trials":1725,"activeCount":99},[],{"trials":1727,"activeCount":99},[1728],{"nctId":1729,"briefTitle":1730,"status":361,"phases":1731,"primaryCompletion":1732,"completion":1732,"start":1733,"enrollment":1734,"conditions":1735,"interventions":1737},"NCT01767701","Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis",[88],"2014-09","2013-04",23,[1736],"Relapsing Remitting Multiple Sclerosis",[1720],{"trials":1739,"activeCount":99},[],{"trials":1741,"activeCount":99},[],{"trials":1743,"activeCount":99},[],{"intervention":1745,"totalTrials":95,"cells":1746},"AZD1656",{"EARLY_PHASE1":1747,"PHASE1":1749,"PHASE2":1751,"PHASE3":1766,"PHASE4":1768,"NA":1770},{"trials":1748,"activeCount":99},[],{"trials":1750,"activeCount":99},[],{"trials":1752,"activeCount":99},[1753],{"nctId":1754,"briefTitle":1755,"status":361,"phases":1756,"primaryCompletion":1757,"completion":1757,"start":1758,"enrollment":807,"conditions":1759,"interventions":1765},"NCT05216172","AZD1656 in Transplantation With Diabetes tO PromoTe Immune TOleraNce",[88],"2022-09-11","2019-12-13",[1760,1761,1762,1763,1764],"Type 2 Diabetes","Diabetes Mellitus, Type 2","Renal Transplant","Kidney Transplant; Complications","End Stage Renal Disease",[1745],{"trials":1767,"activeCount":99},[],{"trials":1769,"activeCount":99},[],{"trials":1771,"activeCount":99},[],{"intervention":1773,"totalTrials":95,"cells":1774},"Famciclovir",{"EARLY_PHASE1":1775,"PHASE1":1777,"PHASE2":1779,"PHASE3":1789,"PHASE4":1791,"NA":1793},{"trials":1776,"activeCount":99},[],{"trials":1778,"activeCount":99},[],{"trials":1780,"activeCount":99},[1781],{"nctId":1782,"briefTitle":1783,"status":450,"phases":1784,"primaryCompletion":1785,"completion":1785,"start":1786,"enrollment":1013,"conditions":1787,"interventions":1788},"NCT05283551","Famciclovir in Multiple Sclerosis",[88],"2023-11-25","2020-11-25",[18],[1773],{"trials":1790,"activeCount":99},[],{"trials":1792,"activeCount":99},[],{"trials":1794,"activeCount":99},[],{"intervention":1796,"totalTrials":95,"cells":1797},"Bintrafusp alfa",{"EARLY_PHASE1":1798,"PHASE1":1800,"PHASE2":1802,"PHASE3":1814,"PHASE4":1816,"NA":1818},{"trials":1799,"activeCount":99},[],{"trials":1801,"activeCount":99},[],{"trials":1803,"activeCount":99},[1804],{"nctId":1805,"briefTitle":1806,"status":450,"phases":1807,"primaryCompletion":1808,"completion":1809,"start":1810,"enrollment":1633,"conditions":1811,"interventions":1813},"NCT04878250","Preoperative Bintrafusp Alfa in Operable Urothelial Carcinoma of the Bladder",[88],"2023-07","2025-01","2021-06",[1812,1525],"Transitional Cell Carcinoma",[1796],{"trials":1815,"activeCount":99},[],{"trials":1817,"activeCount":99},[],{"trials":1819,"activeCount":99},[],{"intervention":1647,"totalTrials":95,"cells":1821},{"EARLY_PHASE1":1822,"PHASE1":1824,"PHASE2":1826,"PHASE3":1832,"PHASE4":1834,"NA":1836},{"trials":1823,"activeCount":99},[],{"trials":1825,"activeCount":99},[],{"trials":1827,"activeCount":99},[1828],{"nctId":1639,"briefTitle":1640,"status":361,"phases":1829,"primaryCompletion":337,"completion":337,"start":1642,"enrollment":1643,"conditions":1830,"interventions":1831},[88],[1645],[1618,1637,1647],{"trials":1833,"activeCount":99},[],{"trials":1835,"activeCount":99},[],{"trials":1837,"activeCount":99},[],{"intervention":1839,"totalTrials":95,"cells":1840},"N-Acetyl Glucosamine",{"EARLY_PHASE1":1841,"PHASE1":1843,"PHASE2":1845,"PHASE3":1858,"PHASE4":1860,"NA":1862},{"trials":1842,"activeCount":99},[],{"trials":1844,"activeCount":99},[],{"trials":1846,"activeCount":99},[1847],{"nctId":1848,"briefTitle":1849,"status":361,"phases":1850,"primaryCompletion":1851,"completion":1851,"start":1852,"enrollment":1853,"conditions":1854,"interventions":1855},"NCT03716115","Therapeutic Approaches to Malnutrition Enteropathy",[88],"2021-04-27","2020-05-04",125,[233],[1839,1856,1857],"Teduglutide","Budesonide",{"trials":1859,"activeCount":99},[],{"trials":1861,"activeCount":99},[],{"trials":1863,"activeCount":99},[],{"intervention":1856,"totalTrials":95,"cells":1865},{"EARLY_PHASE1":1866,"PHASE1":1868,"PHASE2":1870,"PHASE3":1876,"PHASE4":1878,"NA":1880},{"trials":1867,"activeCount":99},[],{"trials":1869,"activeCount":99},[],{"trials":1871,"activeCount":99},[1872],{"nctId":1848,"briefTitle":1849,"status":361,"phases":1873,"primaryCompletion":1851,"completion":1851,"start":1852,"enrollment":1853,"conditions":1874,"interventions":1875},[88],[233],[1839,1856,1857],{"trials":1877,"activeCount":99},[],{"trials":1879,"activeCount":99},[],{"trials":1881,"activeCount":99},[],{"intervention":1857,"totalTrials":95,"cells":1883},{"EARLY_PHASE1":1884,"PHASE1":1886,"PHASE2":1888,"PHASE3":1894,"PHASE4":1896,"NA":1898},{"trials":1885,"activeCount":99},[],{"trials":1887,"activeCount":99},[],{"trials":1889,"activeCount":99},[1890],{"nctId":1848,"briefTitle":1849,"status":361,"phases":1891,"primaryCompletion":1851,"completion":1851,"start":1852,"enrollment":1853,"conditions":1892,"interventions":1893},[88],[233],[1839,1856,1857],{"trials":1895,"activeCount":99},[],{"trials":1897,"activeCount":99},[],{"trials":1899,"activeCount":99},[],{"intervention":404,"totalTrials":95,"cells":1901},{"EARLY_PHASE1":1902,"PHASE1":1904,"PHASE2":1906,"PHASE3":1912,"PHASE4":1914,"NA":1916},{"trials":1903,"activeCount":99},[],{"trials":1905,"activeCount":99},[],{"trials":1907,"activeCount":99},[1908],{"nctId":395,"briefTitle":396,"status":361,"phases":1909,"primaryCompletion":398,"completion":399,"start":400,"enrollment":365,"conditions":1910,"interventions":1911},[88],[402],[355,404],{"trials":1913,"activeCount":99},[],{"trials":1915,"activeCount":99},[],{"trials":1917,"activeCount":99},[],{"intervention":1659,"totalTrials":95,"cells":1919},{"EARLY_PHASE1":1920,"PHASE1":1922,"PHASE2":1924,"PHASE3":1930,"PHASE4":1932,"NA":1934},{"trials":1921,"activeCount":99},[],{"trials":1923,"activeCount":99},[],{"trials":1925,"activeCount":99},[1926],{"nctId":1649,"briefTitle":1650,"status":450,"phases":1927,"primaryCompletion":1652,"completion":1652,"start":1068,"enrollment":1653,"conditions":1928,"interventions":1929},[87,88],[1655,457,1656,1657],[1618,1659],{"trials":1931,"activeCount":99},[],{"trials":1933,"activeCount":99},[],{"trials":1935,"activeCount":99},[],{"intervention":1937,"totalTrials":95,"cells":1938},"Savolitinib",{"EARLY_PHASE1":1939,"PHASE1":1941,"PHASE2":1943,"PHASE3":1958,"PHASE4":1960,"NA":1962},{"trials":1940,"activeCount":99},[],{"trials":1942,"activeCount":99},[],{"trials":1944,"activeCount":99},[1945],{"nctId":1946,"briefTitle":1947,"status":361,"phases":1948,"primaryCompletion":1949,"completion":1949,"start":1950,"enrollment":1951,"conditions":1952,"interventions":1955},"NCT02819596","MEDI4736 Combinations in Metastatic Renal Cell Carcinoma",[88],"2024-07-17","2016-05-03",69,[1953,1954],"Renal Clear Cell Carcinoma","Renal Papillary Cell Carcinoma",[1937,1956,1957],"MEDI4736","Tremelimumab",{"trials":1959,"activeCount":99},[],{"trials":1961,"activeCount":99},[],{"trials":1963,"activeCount":99},[],{"intervention":1956,"totalTrials":95,"cells":1965},{"EARLY_PHASE1":1966,"PHASE1":1968,"PHASE2":1970,"PHASE3":1976,"PHASE4":1978,"NA":1980},{"trials":1967,"activeCount":99},[],{"trials":1969,"activeCount":99},[],{"trials":1971,"activeCount":99},[1972],{"nctId":1946,"briefTitle":1947,"status":361,"phases":1973,"primaryCompletion":1949,"completion":1949,"start":1950,"enrollment":1951,"conditions":1974,"interventions":1975},[88],[1953,1954],[1937,1956,1957],{"trials":1977,"activeCount":99},[],{"trials":1979,"activeCount":99},[],{"trials":1981,"activeCount":99},[],{"intervention":1957,"totalTrials":95,"cells":1983},{"EARLY_PHASE1":1984,"PHASE1":1986,"PHASE2":1988,"PHASE3":1994,"PHASE4":1996,"NA":1998},{"trials":1985,"activeCount":99},[],{"trials":1987,"activeCount":99},[],{"trials":1989,"activeCount":99},[1990],{"nctId":1946,"briefTitle":1947,"status":361,"phases":1991,"primaryCompletion":1949,"completion":1949,"start":1950,"enrollment":1951,"conditions":1992,"interventions":1993},[88],[1953,1954],[1937,1956,1957],{"trials":1995,"activeCount":99},[],{"trials":1997,"activeCount":99},[],{"trials":1999,"activeCount":99},[],{"intervention":2001,"totalTrials":95,"cells":2002},"Tefinostat",{"EARLY_PHASE1":2003,"PHASE1":2005,"PHASE2":2007,"PHASE3":2018,"PHASE4":2020,"NA":2022},{"trials":2004,"activeCount":99},[],{"trials":2006,"activeCount":99},[],{"trials":2008,"activeCount":99},[2009],{"nctId":2010,"briefTitle":2011,"status":450,"phases":2012,"primaryCompletion":2013,"completion":2013,"start":2014,"enrollment":1951,"conditions":2015,"interventions":2017},"NCT02759601","Dose Escalation Trial of Tefinostat for Cancer Associated Inflamation in Hepatocellular Carcinoma (HCC)",[87,88],"2018-12","2013-01",[2016],"Hepatocellular Carcinoma",[2001],{"trials":2019,"activeCount":99},[],{"trials":2021,"activeCount":99},[],{"trials":2023,"activeCount":99},[],{"intervention":2025,"totalTrials":95,"cells":2026},"MPDL3280A",{"EARLY_PHASE1":2027,"PHASE1":2029,"PHASE2":2031,"PHASE3":2042,"PHASE4":2044,"NA":2046},{"trials":2028,"activeCount":99},[],{"trials":2030,"activeCount":99},[],{"trials":2032,"activeCount":99},[2033],{"nctId":2034,"briefTitle":2035,"status":361,"phases":2036,"primaryCompletion":2037,"completion":2037,"start":2038,"enrollment":2039,"conditions":2040,"interventions":2041},"NCT02662309","Preoperative MPDL3280A in Transitional Cell Carcinoma of the Bladder",[88],"2020-06-11","2016-02-01",96,[1525],[2025],{"trials":2043,"activeCount":99},[],{"trials":2045,"activeCount":99},[],{"trials":2047,"activeCount":99},[],{"intervention":459,"totalTrials":95,"cells":2049},{"EARLY_PHASE1":2050,"PHASE1":2052,"PHASE2":2054,"PHASE3":2060,"PHASE4":2062,"NA":2064},{"trials":2051,"activeCount":99},[],{"trials":2053,"activeCount":99},[],{"trials":2055,"activeCount":99},[2056],{"nctId":448,"briefTitle":449,"status":450,"phases":2057,"primaryCompletion":452,"completion":453,"start":454,"enrollment":455,"conditions":2058,"interventions":2059},[88],[457],[459,426,343],{"trials":2061,"activeCount":99},[],{"trials":2063,"activeCount":99},[],{"trials":2065,"activeCount":99},[],{"intervention":2067,"totalTrials":95,"cells":2068},"Enzalutamide",{"EARLY_PHASE1":2069,"PHASE1":2071,"PHASE2":2073,"PHASE3":2087,"PHASE4":2089,"NA":2091},{"trials":2070,"activeCount":99},[],{"trials":2072,"activeCount":99},[],{"trials":2074,"activeCount":99},[2075],{"nctId":2076,"briefTitle":2077,"status":361,"phases":2078,"primaryCompletion":2079,"completion":2079,"start":2080,"enrollment":2081,"conditions":2082,"interventions":2085},"NCT02676986","Short-term Preoperative Treatment With Enzalutamide, Alone or in Combination With Exemestane in Primary Breast Cancer",[88],"2016-12-31","2015-08-10",221,[2083,2084],"Primary Breast Cancer ER+ve","Primary Breast Cancer AR+ve TNBN",[2067,2086],"Exemestane",{"trials":2088,"activeCount":99},[],{"trials":2090,"activeCount":99},[],{"trials":2092,"activeCount":99},[],{"intervention":2086,"totalTrials":95,"cells":2094},{"EARLY_PHASE1":2095,"PHASE1":2097,"PHASE2":2099,"PHASE3":2105,"PHASE4":2107,"NA":2109},{"trials":2096,"activeCount":99},[],{"trials":2098,"activeCount":99},[],{"trials":2100,"activeCount":99},[2101],{"nctId":2076,"briefTitle":2077,"status":361,"phases":2102,"primaryCompletion":2079,"completion":2079,"start":2080,"enrollment":2081,"conditions":2103,"interventions":2104},[88],[2083,2084],[2067,2086],{"trials":2106,"activeCount":99},[],{"trials":2108,"activeCount":99},[],{"trials":2110,"activeCount":99},[],{"intervention":369,"totalTrials":95,"cells":2112},{"EARLY_PHASE1":2113,"PHASE1":2115,"PHASE2":2117,"PHASE3":2123,"PHASE4":2125,"NA":2127},{"trials":2114,"activeCount":99},[],{"trials":2116,"activeCount":99},[],{"trials":2118,"activeCount":99},[2119],{"nctId":359,"briefTitle":360,"status":361,"phases":2120,"primaryCompletion":363,"completion":363,"start":364,"enrollment":365,"conditions":2121,"interventions":2122},[88],[20,367],[50,369,354,370],{"trials":2124,"activeCount":99},[],{"trials":2126,"activeCount":99},[],{"trials":2128,"activeCount":99},[],{"intervention":370,"totalTrials":95,"cells":2130},{"EARLY_PHASE1":2131,"PHASE1":2133,"PHASE2":2135,"PHASE3":2141,"PHASE4":2143,"NA":2145},{"trials":2132,"activeCount":99},[],{"trials":2134,"activeCount":99},[],{"trials":2136,"activeCount":99},[2137],{"nctId":359,"briefTitle":360,"status":361,"phases":2138,"primaryCompletion":363,"completion":363,"start":364,"enrollment":365,"conditions":2139,"interventions":2140},[88],[20,367],[50,369,354,370],{"trials":2142,"activeCount":99},[],{"trials":2144,"activeCount":99},[],{"trials":2146,"activeCount":99},[],{"intervention":2148,"totalTrials":95,"cells":2149},"Prothrombin Complex Concentrate",{"EARLY_PHASE1":2150,"PHASE1":2152,"PHASE2":2154,"PHASE3":2169,"PHASE4":2171,"NA":2173},{"trials":2151,"activeCount":99},[],{"trials":2153,"activeCount":99},[],{"trials":2155,"activeCount":99},[2156],{"nctId":2157,"briefTitle":2158,"status":361,"phases":2159,"primaryCompletion":2160,"completion":2160,"start":2161,"enrollment":2162,"conditions":2163,"interventions":2167},"NCT03715348","Trial of PCC Versus FFP in Patients Undergoing Heart Surgery",[88],"2020-01-29","2019-03-01",50,[2164,2165,2166],"Bleeding","Surgery","Transfusion",[2148,2168],"Fresh Frozen Plasma",{"trials":2170,"activeCount":99},[],{"trials":2172,"activeCount":99},[],{"trials":2174,"activeCount":99},[],{"intervention":2168,"totalTrials":95,"cells":2176},{"EARLY_PHASE1":2177,"PHASE1":2179,"PHASE2":2181,"PHASE3":2187,"PHASE4":2189,"NA":2191},{"trials":2178,"activeCount":99},[],{"trials":2180,"activeCount":99},[],{"trials":2182,"activeCount":99},[2183],{"nctId":2157,"briefTitle":2158,"status":361,"phases":2184,"primaryCompletion":2160,"completion":2160,"start":2161,"enrollment":2162,"conditions":2185,"interventions":2186},[88],[2164,2165,2166],[2148,2168],{"trials":2188,"activeCount":99},[],{"trials":2190,"activeCount":99},[],{"trials":2192,"activeCount":99},[],{"intervention":418,"totalTrials":95,"cells":2194},{"EARLY_PHASE1":2195,"PHASE1":2197,"PHASE2":2199,"PHASE3":2205,"PHASE4":2207,"NA":2209},{"trials":2196,"activeCount":99},[],{"trials":2198,"activeCount":99},[],{"trials":2200,"activeCount":99},[2201],{"nctId":410,"briefTitle":411,"status":334,"phases":2202,"primaryCompletion":413,"completion":414,"start":415,"enrollment":99,"conditions":2203,"interventions":2204},[88],[20],[418,355],{"trials":2206,"activeCount":99},[],{"trials":2208,"activeCount":99},[],{"trials":2210,"activeCount":99},[],{"intervention":2212,"totalTrials":95,"cells":2213},"Oxcarbazepine",{"EARLY_PHASE1":2214,"PHASE1":2216,"PHASE2":2218,"PHASE3":2228,"PHASE4":2230,"NA":2232},{"trials":2215,"activeCount":99},[],{"trials":2217,"activeCount":99},[],{"trials":2219,"activeCount":99},[2220],{"nctId":2221,"briefTitle":2222,"status":361,"phases":2223,"primaryCompletion":2224,"completion":2224,"start":2225,"enrollment":1013,"conditions":2226,"interventions":2227},"NCT02104661","Protective Role of Oxcarbazepine in Multiple Sclerosis",[88],"2018-01-31","2014-10",[18],[2212],{"trials":2229,"activeCount":99},[],{"trials":2231,"activeCount":99},[],{"trials":2233,"activeCount":99},[],{"intervention":1271,"totalTrials":95,"cells":2235},{"EARLY_PHASE1":2236,"PHASE1":2238,"PHASE2":2240,"PHASE3":2246,"PHASE4":2248,"NA":2250},{"trials":2237,"activeCount":99},[],{"trials":2239,"activeCount":99},[],{"trials":2241,"activeCount":99},[2242],{"nctId":1261,"briefTitle":1262,"status":361,"phases":2243,"primaryCompletion":1264,"completion":1265,"start":1266,"enrollment":1267,"conditions":2244,"interventions":2245},[88],[1269],[1271,1272,1273,1274,1275,1276],{"trials":2247,"activeCount":99},[],{"trials":2249,"activeCount":99},[],{"trials":2251,"activeCount":99},[],{"intervention":1272,"totalTrials":95,"cells":2253},{"EARLY_PHASE1":2254,"PHASE1":2256,"PHASE2":2258,"PHASE3":2264,"PHASE4":2266,"NA":2268},{"trials":2255,"activeCount":99},[],{"trials":2257,"activeCount":99},[],{"trials":2259,"activeCount":99},[2260],{"nctId":1261,"briefTitle":1262,"status":361,"phases":2261,"primaryCompletion":1264,"completion":1265,"start":1266,"enrollment":1267,"conditions":2262,"interventions":2263},[88],[1269],[1271,1272,1273,1274,1275,1276],{"trials":2265,"activeCount":99},[],{"trials":2267,"activeCount":99},[],{"trials":2269,"activeCount":99},[],{"intervention":1273,"totalTrials":95,"cells":2271},{"EARLY_PHASE1":2272,"PHASE1":2274,"PHASE2":2276,"PHASE3":2282,"PHASE4":2284,"NA":2286},{"trials":2273,"activeCount":99},[],{"trials":2275,"activeCount":99},[],{"trials":2277,"activeCount":99},[2278],{"nctId":1261,"briefTitle":1262,"status":361,"phases":2279,"primaryCompletion":1264,"completion":1265,"start":1266,"enrollment":1267,"conditions":2280,"interventions":2281},[88],[1269],[1271,1272,1273,1274,1275,1276],{"trials":2283,"activeCount":99},[],{"trials":2285,"activeCount":99},[],{"trials":2287,"activeCount":99},[],{"intervention":1276,"totalTrials":95,"cells":2289},{"EARLY_PHASE1":2290,"PHASE1":2292,"PHASE2":2294,"PHASE3":2300,"PHASE4":2302,"NA":2304},{"trials":2291,"activeCount":99},[],{"trials":2293,"activeCount":99},[],{"trials":2295,"activeCount":99},[2296],{"nctId":1261,"briefTitle":1262,"status":361,"phases":2297,"primaryCompletion":1264,"completion":1265,"start":1266,"enrollment":1267,"conditions":2298,"interventions":2299},[88],[1269],[1271,1272,1273,1274,1275,1276],{"trials":2301,"activeCount":99},[],{"trials":2303,"activeCount":99},[],{"trials":2305,"activeCount":99},[],{"intervention":2307,"totalTrials":95,"cells":2308},"Bacterial Lysate",{"EARLY_PHASE1":2309,"PHASE1":2311,"PHASE2":2313,"PHASE3":2326,"PHASE4":2328,"NA":2330},{"trials":2310,"activeCount":99},[],{"trials":2312,"activeCount":99},[],{"trials":2314,"activeCount":99},[2315],{"nctId":2316,"briefTitle":2317,"status":361,"phases":2318,"primaryCompletion":2319,"completion":2319,"start":2320,"enrollment":2321,"conditions":2322,"interventions":2325},"NCT05064631","Bacterial Lysate In Preventing Asthma",[88],"2024-06-13","2022-01-12",173,[2323,2324,1592],"Respiratory Tract Infections","Pediatric Respiratory Diseases",[2307],{"trials":2327,"activeCount":99},[],{"trials":2329,"activeCount":99},[],{"trials":2331,"activeCount":99},[],{"intervention":2333,"totalTrials":95,"cells":2334},"humanised monoclonal antibody, veltuzumab",{"EARLY_PHASE1":2335,"PHASE1":2337,"PHASE2":2339,"PHASE3":2353,"PHASE4":2355,"NA":2357},{"trials":2336,"activeCount":99},[],{"trials":2338,"activeCount":99},[],{"trials":2340,"activeCount":99},[2341],{"nctId":2342,"briefTitle":2343,"status":450,"phases":2344,"primaryCompletion":2345,"completion":2345,"start":2346,"enrollment":2347,"conditions":2348,"interventions":2350},"NCT01279707","Monoclonal Antibodies in Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) (MARALL)",[87,88],"2014-08","2010-01",55,[2349],"Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia",[2333,2351,2352],"humanised monoclonal antibody epratuzumab","humanised monoclonal antibodies veltuzumab and epratuzumab",{"trials":2354,"activeCount":99},[],{"trials":2356,"activeCount":99},[],{"trials":2358,"activeCount":99},[],{"intervention":2351,"totalTrials":95,"cells":2360},{"EARLY_PHASE1":2361,"PHASE1":2363,"PHASE2":2365,"PHASE3":2371,"PHASE4":2373,"NA":2375},{"trials":2362,"activeCount":99},[],{"trials":2364,"activeCount":99},[],{"trials":2366,"activeCount":99},[2367],{"nctId":2342,"briefTitle":2343,"status":450,"phases":2368,"primaryCompletion":2345,"completion":2345,"start":2346,"enrollment":2347,"conditions":2369,"interventions":2370},[87,88],[2349],[2333,2351,2352],{"trials":2372,"activeCount":99},[],{"trials":2374,"activeCount":99},[],{"trials":2376,"activeCount":99},[],{"intervention":2352,"totalTrials":95,"cells":2378},{"EARLY_PHASE1":2379,"PHASE1":2381,"PHASE2":2383,"PHASE3":2389,"PHASE4":2391,"NA":2393},{"trials":2380,"activeCount":99},[],{"trials":2382,"activeCount":99},[],{"trials":2384,"activeCount":99},[2385],{"nctId":2342,"briefTitle":2343,"status":450,"phases":2386,"primaryCompletion":2345,"completion":2345,"start":2346,"enrollment":2347,"conditions":2387,"interventions":2388},[87,88],[2349],[2333,2351,2352],{"trials":2390,"activeCount":99},[],{"trials":2392,"activeCount":99},[],{"trials":2394,"activeCount":99},[],{"intervention":776,"totalTrials":378,"cells":2396},{"EARLY_PHASE1":2397,"PHASE1":2403,"PHASE2":2414,"PHASE3":2416,"PHASE4":2418,"NA":2420},{"trials":2398,"activeCount":99},[2399],{"nctId":766,"briefTitle":767,"status":361,"phases":2400,"primaryCompletion":769,"completion":770,"start":771,"enrollment":772,"conditions":2401,"interventions":2402},[86],[774],[776,751],{"trials":2404,"activeCount":99},[2405],{"nctId":2406,"briefTitle":2407,"status":361,"phases":2408,"primaryCompletion":415,"completion":2409,"start":2410,"enrollment":2411,"conditions":2412,"interventions":2413},"NCT02715635","Influence of Dietary Nitrate on Vascular Dysfunction and Inflammation",[87],"2021-08-01","2016-04",78,[15],[776],{"trials":2415,"activeCount":99},[],{"trials":2417,"activeCount":99},[],{"trials":2419,"activeCount":99},[],{"trials":2421,"activeCount":99},[],{"intervention":1680,"totalTrials":95,"cells":2423},{"EARLY_PHASE1":2424,"PHASE1":2426,"PHASE2":2432,"PHASE3":2434,"PHASE4":2436,"NA":2438},{"trials":2425,"activeCount":99},[],{"trials":2427,"activeCount":99},[2428],{"nctId":1673,"briefTitle":1674,"status":361,"phases":2429,"primaryCompletion":1676,"completion":1676,"start":1242,"enrollment":9,"conditions":2430,"interventions":2431},[87],[1678],[1680,1637],{"trials":2433,"activeCount":99},[],{"trials":2435,"activeCount":99},[],{"trials":2437,"activeCount":99},[],{"trials":2439,"activeCount":99},[],{"intervention":342,"totalTrials":95,"cells":2441},{"EARLY_PHASE1":2442,"PHASE1":2444,"PHASE2":2450,"PHASE3":2452,"PHASE4":2454,"NA":2456},{"trials":2443,"activeCount":99},[],{"trials":2445,"activeCount":99},[2446],{"nctId":332,"briefTitle":333,"status":334,"phases":2447,"primaryCompletion":336,"completion":337,"start":338,"enrollment":99,"conditions":2448,"interventions":2449},[87],[340],[50,342,343,344],{"trials":2451,"activeCount":99},[],{"trials":2453,"activeCount":99},[],{"trials":2455,"activeCount":99},[],{"trials":2457,"activeCount":99},[],{"intervention":344,"totalTrials":95,"cells":2459},{"EARLY_PHASE1":2460,"PHASE1":2462,"PHASE2":2468,"PHASE3":2470,"PHASE4":2472,"NA":2474},{"trials":2461,"activeCount":99},[],{"trials":2463,"activeCount":99},[2464],{"nctId":332,"briefTitle":333,"status":334,"phases":2465,"primaryCompletion":336,"completion":337,"start":338,"enrollment":99,"conditions":2466,"interventions":2467},[87],[340],[50,342,343,344],{"trials":2469,"activeCount":99},[],{"trials":2471,"activeCount":99},[],{"trials":2473,"activeCount":99},[],{"trials":2475,"activeCount":99},[],{"intervention":2477,"totalTrials":378,"cells":2478},"Alemtuzumab",{"EARLY_PHASE1":2479,"PHASE1":2481,"PHASE2":2483,"PHASE3":2485,"PHASE4":2487,"NA":2489},{"trials":2480,"activeCount":99},[],{"trials":2482,"activeCount":99},[],{"trials":2484,"activeCount":99},[],{"trials":2486,"activeCount":99},[],{"trials":2488,"activeCount":99},[],{"trials":2490,"activeCount":99},[2491,2500],{"nctId":2492,"briefTitle":2493,"status":361,"phases":2494,"primaryCompletion":2495,"completion":2495,"start":2496,"enrollment":2497,"conditions":2498,"interventions":2499},"NCT06310343","ADAs to Alemtuzumab",[],"2025-10-17","2022-07-12",15,[18],[2477],{"nctId":2501,"briefTitle":2502,"status":1629,"phases":2503,"primaryCompletion":2504,"completion":2504,"start":2505,"enrollment":2506,"conditions":2507,"interventions":2508},"NCT03250169","Neurofilaments for NEDA Assessing in MS",[],"2022-01-28","2017-08-01",21,[18],[2477],{"intervention":2510,"totalTrials":95,"cells":2511},"Nicotine",{"EARLY_PHASE1":2512,"PHASE1":2514,"PHASE2":2516,"PHASE3":2518,"PHASE4":2520,"NA":2522},{"trials":2513,"activeCount":99},[],{"trials":2515,"activeCount":99},[],{"trials":2517,"activeCount":99},[],{"trials":2519,"activeCount":99},[],{"trials":2521,"activeCount":99},[],{"trials":2523,"activeCount":99},[2524],{"nctId":2525,"briefTitle":2526,"status":361,"phases":2527,"primaryCompletion":2528,"completion":2528,"start":2014,"enrollment":2529,"conditions":2530,"interventions":2533},"NCT01454362","Effect of the Electronic Cigarette on Withdrawal Symptoms",[91],"2013-03",51,[2531,2532],"Mental and Behavioral Disorders","Withdrawal State",[2510],{"intervention":2535,"totalTrials":95,"cells":2536},"DNA analysis",{"EARLY_PHASE1":2537,"PHASE1":2539,"PHASE2":2541,"PHASE3":2543,"PHASE4":2545,"NA":2547},{"trials":2538,"activeCount":99},[],{"trials":2540,"activeCount":99},[],{"trials":2542,"activeCount":99},[],{"trials":2544,"activeCount":99},[],{"trials":2546,"activeCount":99},[],{"trials":2548,"activeCount":99},[2549],{"nctId":2550,"briefTitle":2551,"status":450,"phases":2552,"primaryCompletion":2553,"start":2554,"enrollment":986,"conditions":2555,"interventions":2556},"NCT00935233","Study of Biomarkers in Blood and\u002For Tumor Tissue Samples From Patients With Ductal Carcinoma in Situ and From Healthy Volunteers",[],"2010-07","2008-07",[20],[2535,2557,2558],"polymorphism analysis","protein analysis",{"intervention":2557,"totalTrials":95,"cells":2560},{"EARLY_PHASE1":2561,"PHASE1":2563,"PHASE2":2565,"PHASE3":2567,"PHASE4":2569,"NA":2571},{"trials":2562,"activeCount":99},[],{"trials":2564,"activeCount":99},[],{"trials":2566,"activeCount":99},[],{"trials":2568,"activeCount":99},[],{"trials":2570,"activeCount":99},[],{"trials":2572,"activeCount":99},[2573],{"nctId":2550,"briefTitle":2551,"status":450,"phases":2574,"primaryCompletion":2553,"start":2554,"enrollment":986,"conditions":2575,"interventions":2576},[],[20],[2535,2557,2558],{"intervention":2558,"totalTrials":95,"cells":2578},{"EARLY_PHASE1":2579,"PHASE1":2581,"PHASE2":2583,"PHASE3":2585,"PHASE4":2587,"NA":2589},{"trials":2580,"activeCount":99},[],{"trials":2582,"activeCount":99},[],{"trials":2584,"activeCount":99},[],{"trials":2586,"activeCount":99},[],{"trials":2588,"activeCount":99},[],{"trials":2590,"activeCount":99},[2591],{"nctId":2550,"briefTitle":2551,"status":450,"phases":2592,"primaryCompletion":2553,"start":2554,"enrollment":986,"conditions":2593,"interventions":2594},[],[20],[2535,2557,2558],{"intervention":2596,"totalTrials":95,"cells":2597},"Anti-TNF Biologics Therapy",{"EARLY_PHASE1":2598,"PHASE1":2600,"PHASE2":2602,"PHASE3":2604,"PHASE4":2606,"NA":2608},{"trials":2599,"activeCount":99},[],{"trials":2601,"activeCount":99},[],{"trials":2603,"activeCount":99},[],{"trials":2605,"activeCount":99},[],{"trials":2607,"activeCount":99},[],{"trials":2609,"activeCount":99},[2610],{"nctId":2611,"briefTitle":2612,"status":361,"phases":2613,"primaryCompletion":2614,"completion":2614,"start":2615,"enrollment":2616,"conditions":2617,"interventions":2619},"NCT02620189","Th17 Responses Evaluated in RA Patients on Inhibitors of TNFα",[],"2017-05-24","2015-03",60,[2618],"Rheumatoid Arthritis",[2596],{"intervention":2621,"totalTrials":95,"cells":2622},"Peripheral blood and induced sputum sampling",{"EARLY_PHASE1":2623,"PHASE1":2625,"PHASE2":2627,"PHASE3":2629,"PHASE4":2631,"NA":2633},{"trials":2624,"activeCount":99},[],{"trials":2626,"activeCount":99},[],{"trials":2628,"activeCount":99},[],{"trials":2630,"activeCount":99},[],{"trials":2632,"activeCount":99},[],{"trials":2634,"activeCount":99},[2635],{"nctId":2636,"briefTitle":2637,"status":361,"phases":2638,"primaryCompletion":2639,"completion":2639,"start":2640,"enrollment":386,"conditions":2641,"interventions":2643},"NCT02802722","Does Vitamin D Supplementation Enhance Resolution of Inflammation After Community-acquired Pneumonia?",[91],"2018-12-31","2017-02-24",[2642],"Pneumonia",[2621],{"intervention":2645,"totalTrials":95,"cells":2646},"Zirconia surface implant and guided bone regeneration",{"EARLY_PHASE1":2647,"PHASE1":2649,"PHASE2":2651,"PHASE3":2653,"PHASE4":2655,"NA":2657},{"trials":2648,"activeCount":99},[],{"trials":2650,"activeCount":99},[],{"trials":2652,"activeCount":99},[],{"trials":2654,"activeCount":99},[],{"trials":2656,"activeCount":99},[],{"trials":2658,"activeCount":99},[2659],{"nctId":2660,"briefTitle":2661,"status":361,"phases":2662,"primaryCompletion":2663,"completion":2663,"start":2664,"enrollment":2665,"conditions":2666,"interventions":2671},"NCT05890469","Effect of Implant Surface Material and Topography on Bone Regeneration.",[91],"2025-01-27","2023-12-01",12,[2667,2668,2669,2670],"Dental Implant","Guided Bone Regeneration","Biomarkers","Saliva",[2645,2672],"Hydrophilic titanium surface implant and guided bone regeneration",{"intervention":2672,"totalTrials":95,"cells":2674},{"EARLY_PHASE1":2675,"PHASE1":2677,"PHASE2":2679,"PHASE3":2681,"PHASE4":2683,"NA":2685},{"trials":2676,"activeCount":99},[],{"trials":2678,"activeCount":99},[],{"trials":2680,"activeCount":99},[],{"trials":2682,"activeCount":99},[],{"trials":2684,"activeCount":99},[],{"trials":2686,"activeCount":99},[2687],{"nctId":2660,"briefTitle":2661,"status":361,"phases":2688,"primaryCompletion":2663,"completion":2663,"start":2664,"enrollment":2665,"conditions":2689,"interventions":2690},[91],[2667,2668,2669,2670],[2645,2672],{"intervention":2692,"totalTrials":95,"cells":2693},"C-type natriuretic peptide",{"EARLY_PHASE1":2694,"PHASE1":2696,"PHASE2":2698,"PHASE3":2700,"PHASE4":2702,"NA":2704},{"trials":2695,"activeCount":99},[],{"trials":2697,"activeCount":99},[],{"trials":2699,"activeCount":99},[],{"trials":2701,"activeCount":99},[],{"trials":2703,"activeCount":99},[],{"trials":2705,"activeCount":99},[2706],{"nctId":2707,"briefTitle":2708,"status":334,"phases":2709,"primaryCompletion":2710,"completion":2711,"start":2712,"enrollment":99,"conditions":2713,"interventions":2715},"NCT01075776","The Effects of C-type Natriuretic Peptide on Human Forearm Blood Vessels",[91],"2022-01","2023-01","2020-01",[2714],"Ischaemia-reperfusion (IR) Injury",[2692,2716,2717],"Saline","Acetylcholine",{"intervention":2716,"totalTrials":95,"cells":2719},{"EARLY_PHASE1":2720,"PHASE1":2722,"PHASE2":2724,"PHASE3":2726,"PHASE4":2728,"NA":2730},{"trials":2721,"activeCount":99},[],{"trials":2723,"activeCount":99},[],{"trials":2725,"activeCount":99},[],{"trials":2727,"activeCount":99},[],{"trials":2729,"activeCount":99},[],{"trials":2731,"activeCount":99},[2732],{"nctId":2707,"briefTitle":2708,"status":334,"phases":2733,"primaryCompletion":2710,"completion":2711,"start":2712,"enrollment":99,"conditions":2734,"interventions":2735},[91],[2714],[2692,2716,2717],{"intervention":2717,"totalTrials":95,"cells":2737},{"EARLY_PHASE1":2738,"PHASE1":2740,"PHASE2":2742,"PHASE3":2744,"PHASE4":2746,"NA":2748},{"trials":2739,"activeCount":99},[],{"trials":2741,"activeCount":99},[],{"trials":2743,"activeCount":99},[],{"trials":2745,"activeCount":99},[],{"trials":2747,"activeCount":99},[],{"trials":2749,"activeCount":99},[2750],{"nctId":2707,"briefTitle":2708,"status":334,"phases":2751,"primaryCompletion":2710,"completion":2711,"start":2712,"enrollment":99,"conditions":2752,"interventions":2753},[91],[2714],[2692,2716,2717],{"intervention":2755,"totalTrials":95,"cells":2756},"Cinnarizine",{"EARLY_PHASE1":2757,"PHASE1":2759,"PHASE2":2761,"PHASE3":2763,"PHASE4":2765,"NA":2767},{"trials":2758,"activeCount":99},[],{"trials":2760,"activeCount":99},[],{"trials":2762,"activeCount":99},[],{"trials":2764,"activeCount":99},[],{"trials":2766,"activeCount":99},[],{"trials":2768,"activeCount":99},[2769],{"nctId":2770,"briefTitle":2771,"status":361,"phases":2772,"primaryCompletion":2773,"completion":2774,"start":2775,"enrollment":2497,"conditions":2776,"interventions":2779},"NCT05686993","Effect of a Proposed Cav1.3 Inhibitor in Primary Aldosteronism",[91],"2023-09-01","2023-09-06","2023-04-24",[2777,2778],"Primary Aldosteronism","Endocrine Hypertension",[2755,2780],"NIFEdipine ER",{"intervention":2780,"totalTrials":95,"cells":2782},{"EARLY_PHASE1":2783,"PHASE1":2785,"PHASE2":2787,"PHASE3":2789,"PHASE4":2791,"NA":2793},{"trials":2784,"activeCount":99},[],{"trials":2786,"activeCount":99},[],{"trials":2788,"activeCount":99},[],{"trials":2790,"activeCount":99},[],{"trials":2792,"activeCount":99},[],{"trials":2794,"activeCount":99},[2795],{"nctId":2770,"briefTitle":2771,"status":361,"phases":2796,"primaryCompletion":2773,"completion":2774,"start":2775,"enrollment":2497,"conditions":2797,"interventions":2798},[91],[2777,2778],[2755,2780],{"intervention":2800,"totalTrials":95,"cells":2801},"Corsodyl® Alcohol free -0.2 % Chlorhexidine digluconate",{"EARLY_PHASE1":2802,"PHASE1":2804,"PHASE2":2806,"PHASE3":2808,"PHASE4":2810,"NA":2812},{"trials":2803,"activeCount":99},[],{"trials":2805,"activeCount":99},[],{"trials":2807,"activeCount":99},[],{"trials":2809,"activeCount":99},[],{"trials":2811,"activeCount":99},[],{"trials":2813,"activeCount":99},[2814],{"nctId":2815,"briefTitle":2816,"status":361,"phases":2817,"primaryCompletion":2818,"completion":2818,"start":2819,"enrollment":2820,"conditions":2821,"interventions":2824},"NCT04723446","Efficacy of Mouthwashes in Reducing Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load in the Saliva",[91],"2021-10-25","2021-05-19",54,[2822,2823],"Covid19","Coronavirus",[2800,2825],"Colgate Peroxyl® -1.5% Hydrogen peroxide",{"intervention":2825,"totalTrials":95,"cells":2827},{"EARLY_PHASE1":2828,"PHASE1":2830,"PHASE2":2832,"PHASE3":2834,"PHASE4":2836,"NA":2838},{"trials":2829,"activeCount":99},[],{"trials":2831,"activeCount":99},[],{"trials":2833,"activeCount":99},[],{"trials":2835,"activeCount":99},[],{"trials":2837,"activeCount":99},[],{"trials":2839,"activeCount":99},[2840],{"nctId":2815,"briefTitle":2816,"status":361,"phases":2841,"primaryCompletion":2818,"completion":2818,"start":2819,"enrollment":2820,"conditions":2842,"interventions":2843},[91],[2822,2823],[2800,2825]]